About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Lenalidomide

Company: Janssen Research & Development, LLC
Mechanism: Mechanism not yet reported
Route: Route not yet reported
Recruiting trials: 61 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

61 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 24, 2026

Trial details

Recruiting NCT NCT02343042

Selinexor and Backbone Treatments of Multiple Myeloma Patients

Not yet reported, Not yet reported Karyopharm Therapeutics Inc 300 participants Est. completion 2027-04 25 sites Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Recruiting NCT NCT03011814

Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma

Not yet reported, Not yet reported City of Hope Medical Center 78 participants Est. completion 2030-04-14 4 sites Stand-alone

Other conditions: Folliculotropic Mycosis Fungoides, Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Mycosis Fungoides, Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Mycosis Fungoides, Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, Sezary Syndrome, Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma
View official trial listing →
Recruiting NCT NCT04025450

Comparation of Chidamide Plus VRD (Bortezomib, Lenalidomide, Dexamethasone) With VRD Regimen for Primary High-Risk Multiple Myeloma Patients

Not yet reported, Not yet reported The First Affiliated Hospital of Soochow University 50 participants Est. completion 2029-07-15 1 site Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Recruiting NCT NCT04068597

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

Not yet reported, Not yet reported CellCentric Ltd. 250 participants Est. completion 2027-03-31 39 sites Stand-alone

Other conditions: Haematological Malignancy, Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma, Higher-risk Myelodysplastic Syndrome, Peripheral T Cell Lymphoma
View official trial listing →
Recruiting NCT NCT04301076

Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)

Not yet reported National Cancer Institute (NCI) 30 participants Est. completion 2027-06-30 19 sites Stand-alone

Other conditions: Acute Adult T-Cell Leukemia/Lymphoma, Adult T-Cell Leukemia/Lymphoma, Chronic Adult T-Cell Leukemia/Lymphoma, HTLV-1 Infection
View official trial listing →
Recruiting NCT NCT04432714

Lenalidomide in Combination With R-DA-EPOCH in Patients With Untreated DLBCL With MYC Rearrangement

Not yet reported, Not yet reported The First Affiliated Hospital with Nanjing Medical University 81 participants Est. completion 2026-12-31 1 site Stand-alone

Other conditions: DLBCL, Untreated, MYC Gene Rearrangement
View official trial listing →
Recruiting NCT NCT04627753

Study of Lenalidomide/Rituximab Maintenance for Transplantation Ineligible Patients With PCNSL.

Not yet reported Kim, Seok Jin 30 participants Est. completion 2028-11-02 1 site Stand-alone

Other conditions: Primary CNS Lymphoma
View official trial listing →
Recruiting NCT NCT04922567

Efficacy and Safety of Lenalidomide Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma

Not yet reported Second Affiliated Hospital, Zhejiang University, School of Medicine 289 participants Est. completion 2026-12-31 1 site Stand-alone

Other conditions: Peripheral T-Cell Lymphoma, Lenalidomide, CHOP
View official trial listing →
Recruiting NCT NCT04991103

Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)

Not yet reported University of Alabama at Birmingham 40 participants Est. completion 2028-08-27 1 site Stand-alone

Other conditions: Multiple Myeloma, Amyloidosis
View official trial listing →
Recruiting NCT NCT05020236

A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments

Not yet reported Pfizer 893 participants Est. completion 2027-05-31 237 sites

Other conditions: Multiple Myeloma
View official trial listing →
Recruiting NCT NCT05091372

Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma

Not yet reported M.D. Anderson Cancer Center 94 participants Est. completion 2027-12-31 1 site Stand-alone

Other conditions: Myeloma Multiple
View official trial listing →
Recruiting NCT NCT05145400

Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma

Not yet reported UNC Lineberger Comprehensive Cancer Center 50 participants Est. completion 2033-05-28 5 sites Stand-alone

Other conditions: Multiple Myeloma, Cancer
View official trial listing →
Recruiting NCT NCT05182957

Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma

Not yet reported The First Affiliated Hospital of Soochow University 31 participants Est. completion 2026-06-15 1 site Stand-alone

Other conditions: Relapsed/Refractory Peripheral T-cell Lymphoma
View official trial listing →
Recruiting NCT NCT05203003

Prospective Evaluation of the Prognostic Impact of Measurable Residual Disease (MRD) Within a Phase III Study Comparing a Fixed Duration Therapy Versus Continuous Therapy With Daratumumab, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma Requiring a First Salvage Treatment.

Assistance Publique - Hôpitaux de Paris 260 participants Est. completion 2028-12 1 site

Other conditions: Multiple Myeloma
View official trial listing →
Recruiting NCT NCT05248633

Chemotherapy Combined With Radiotherapy Versus Radiotherapy Alone for Solitary Plasmacytoma

Not yet reported Peking Union Medical College Hospital 220 participants Est. completion 2026-10 1 site Stand-alone

Other conditions: Solitary Plasmacytoma
View official trial listing →
Recruiting NCT NCT05469893

Immuno-PRISM (PRecision Intervention Smoldering Myeloma)

Not yet reported Irene Ghobrial, MD 52 participants Est. completion 2030-07-31 3 sites

Other conditions: High-risk Smoldering Multiple Myeloma, Smoldering Multiple Myeloma, Multiple Myeloma
View official trial listing →
Recruiting NCT NCT05552222

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

Not yet reported Janssen Research & Development, LLC 1590 participants Est. completion 2033-10-28 270 sites Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Recruiting NCT NCT05572229

Study of Teclistamab in Combination in Elderly Patients With Multiple Myeloma

Not yet reported University Hospital, Lille 74 participants Est. completion 2030-09 29 sites Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Recruiting NCT NCT05722405

Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple Myeloma

Not yet reported Second Affiliated Hospital, Zhejiang University, School of Medicine 100 participants Est. completion 2028-07-31 1 site Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Recruiting NCT NCT05828459

First-in-human Study of OT-A201 in Patients With Selected Hematological Malignancies and Solid Tumors

Not yet reported Onward Therapeutics 150 participants Est. completion 2027-07 4 sites Stand-alone

Other conditions: Hematological Malignancy, Solid Tumor
View official trial listing →
Recruiting NCT NCT05899621

A Real-world Study of Obinutuzumab-based Therapy for Previously Untreated FL

Ruijin Hospital 332 participants Est. completion 2027-06-30 1 site

Other conditions: Follicular Lymphoma
View official trial listing →
Recruiting NCT NCT05910801

Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Not yet reported Academic and Community Cancer Research United 100 participants Est. completion 2030-12-30 2 sites Stand-alone

Other conditions: Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
View official trial listing →
Recruiting NCT NCT05992597

ZR2 Sequential Immunochemotherapy for Newly Treated MCL

Not yet reported Zhejiang Cancer Hospital 48 participants Est. completion 2026-12-01 1 site Stand-alone

Other conditions: Rituximab, Lenalidomide, Zebutinib ，Mantle Cell Lymphoma
View official trial listing →
Recruiting NCT NCT06006117

Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma

Not yet reported The Lymphoma Academic Research Organisation 260 participants Est. completion 2032-09 48 sites Stand-alone

Other conditions: Marginal Zone Lymphoma
View official trial listing →
Recruiting NCT NCT06039735

Cardiac Toxicity and Prognostic Value of New Echocardiographic Indicators in the Treatment of Primary Multiple Myeloma

Qilu Hospital of Shandong University 50 participants Est. completion 2028-12 1 site

Other conditions: Multiple Myeloma
View official trial listing →
Recruiting NCT NCT06082102

Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma

Not yet reported Beijing InnoCare Pharma Tech Co., Ltd. 324 participants Est. completion 2030-02-25 19 sites

Other conditions: Relapsed/Refractory Marginal Zone Lymphoma
View official trial listing →
Recruiting NCT NCT06084936

A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma

Not yet reported Hoffmann-La Roche 182 participants Est. completion 2028-03-31 82 sites

Other conditions: Lymphoma
View official trial listing →
Recruiting NCT NCT06087653

Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM)

Not yet reported, Not yet reported Starton Therapeutics, Inc 24 participants Est. completion 2028-03-31 2 sites Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Recruiting NCT NCT06151080

Lenalidomide Combined With G-CHOP in the Treatment of Newly Diagnosed DLBCL With FL

Not yet reported The First Affiliated Hospital of Xiamen University 38 participants Est. completion 2027-12-31 1 site Stand-alone

Other conditions: DLBCL - Diffuse Large B Cell Lymphoma, Follicular Lymphoma
View official trial listing →
Recruiting NCT NCT06152575

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

Not yet reported Pfizer 492 participants Est. completion 2027-12-30 270 sites

Other conditions: Multiple Myeloma
View official trial listing →
Recruiting NCT NCT06207799

Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma

Not yet reported M.D. Anderson Cancer Center 40 participants Est. completion 2031-12-31 1 site Stand-alone

Other conditions: Multiple Myeloma, Post-transplant MRD-guided Maintenance Therapy, Pre-transplant Purging
View official trial listing →
Recruiting NCT NCT06284122

Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5

Not yet reported The Lymphoma Academic Research Organisation 790 participants Est. completion 2034-04 116 sites Stand-alone

Other conditions: Follicular Lymphoma
View official trial listing →
Recruiting NCT NCT06299553

Study to Evaluate the Effectiveness of Tafasitamab in Combination With Lenalidomide Followed by Tafasitamab Monotherapy in Relapsed or Refractory Diffuse Large B-cell Lymphoma Non-transplant Eligible Patients in Italy (PRO-MIND)

Incyte Biosciences Italy S.r.l 200 participants Est. completion 2027-06-30 1 site

Other conditions: DLBCL - Diffuse Large B Cell Lymphoma
View official trial listing →
Recruiting NCT NCT06409702

Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection

Not yet reported The First Affiliated Hospital of Soochow University 59 participants Est. completion 2027-12-31 1 site Stand-alone

Other conditions: Newly Diagnosed, High Risk, MRD, Multiple Myeloma
View official trial listing →
Recruiting NCT NCT06414148

MRD-Directed Consolidation With Epcor-only or Epcor-R2 Post Anti-CD19 CAR TCell Therapy for Large B-Cell Lymphoma

Not yet reported Peter MacCallum Cancer Centre, Australia 40 participants Est. completion 2028-05 6 sites Stand-alone

Other conditions: Relapsed/Refractory Large B-cell Lymphoma
View official trial listing →
Recruiting NCT NCT06503263

Zanubrutinib and Lenalidomide as Maintenance Therapy in DLBCL

Not yet reported Navy General Hospital, Beijing 240 participants Est. completion 2030-12-30 1 site Stand-alone

Other conditions: Diffuse Large B-cell Lymphoma
View official trial listing →
Recruiting NCT NCT06517017

Use of Isatuximab, Dexamethasone and Lenalidomide in a Go-Slow Fashion for Ultra-Frail Patients With Multiple Myeloma

Not yet reported University of Utah 40 participants Est. completion 2027-11 1 site Stand-alone

Other conditions: Multiple Myeloma, Plasma Cell Leukemia
View official trial listing →
Recruiting NCT NCT06521255

Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Not yet reported Beijing InnoCare Pharma Tech Co., Ltd. 244 participants Est. completion 2029-12 20 sites Stand-alone

Other conditions: DLBCL
View official trial listing →
Recruiting NCT NCT06534463

Registry Study of Chinese Patients with Marginal Zone Lymphoma (MOTIVE)

Ruijin Hospital 500 participants Est. completion 2029-09-01 1 site

Other conditions: Marginal Zone Lymphoma
View official trial listing →
Recruiting NCT NCT06541860

DAratumumab and REvlimid REfractory MM

Fondazione IRCCS Policlinico San Matteo di Pavia 100 participants Est. completion 2028-08-21 1 site

Other conditions: Multiple Myeloma
View official trial listing →
Recruiting NCT NCT06615479

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

Not yet reported Juno Therapeutics, Inc., a Bristol-Myers Squibb Company 440 participants Est. completion 2032-06-22 141 sites

Other conditions: Relapsed or Refractory Multiple Myeloma (RRMM)
View official trial listing →
Recruiting NCT NCT06649812

Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

Not yet reported National Cancer Institute (NCI) 120 participants Est. completion 2028-09-01 104 sites Stand-alone

Other conditions: High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified, Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified, Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
View official trial listing →
Recruiting NCT NCT06674096

RLC Followed by CR-CHOP in Elderly Patients with Newly-diagnosed DEL

Not yet reported Zhejiang Cancer Hospital 44 participants Est. completion 2030-06-30 1 site Stand-alone

Other conditions: Double-expressor Lymphoma
View official trial listing →
Recruiting NCT NCT06697483

Risk Stratification and MRD-driven Maintenance for MM After ASCT

Not yet reported Peking University People's Hospital 100 participants Est. completion 2027-12-31 4 sites

Other conditions: Multiple Myeloma
View official trial listing →
Recruiting NCT NCT06768489

A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma

Not yet reported Janssen Research & Development, LLC 240 participants Est. completion 2029-06-29 16 sites Stand-alone

Other conditions: Multiple Myeloma, Smoldering Multiple Myeloma, Immunoglobulin Light-chain Amyloidosis
View official trial listing →
Recruiting NCT NCT06803693

Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL

Not yet reported Ruijin Hospital 152 participants Est. completion 2028-12-31 1 site Stand-alone

Other conditions: Diffuse Large B-Cell Lymphoma
View official trial listing →
Recruiting NCT NCT06892522

A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations

Not yet reported, Not yet reported AbbVie 602 participants Est. completion 2035-12 34 sites Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Recruiting NCT NCT06918002

Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients

Not yet reported Intergroupe Francophone du Myelome 824 participants Est. completion 2036-05 64 sites Stand-alone

Other conditions: Multiple Myeloma, Newly Diagnosed
View official trial listing →
Recruiting NCT NCT06931652

Study of Epcoritamab in R/R Primary Diffuse Large B-cell Lymphoma of the CNS Treated With Lenalidomide and Rituximab

Not yet reported The Lymphoma Academic Research Organisation 60 participants Est. completion 2030-01 13 sites Stand-alone

Other conditions: Primary CNS Lymphoma (PCNSL)
View official trial listing →
Recruiting NCT NCT06932562

A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant

Not yet reported European Myeloma Network B.V. 1000 participants Est. completion 2036-12 59 sites Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Recruiting NCT NCT07045909

Efficacy and Safety of Anitocabtagene Autoleucel in Participants With Newly Diagnosed Multiple Myeloma (GEM-AnitoFIRST)

Not yet reported PETHEMA Foundation 30 participants Est. completion 2030-03-31 10 sites Stand-alone

Other conditions: De Novo Multiple Myeloma, Anitocabtagene Autoleucel
View official trial listing →
Recruiting NCT NCT07068165

A Randomized Controlled Study of the Efficacy and Safety of Lenalidomide in the Treatment of Active IgG4-related Disease

Not yet reported, Not yet reported Peking Union Medical College Hospital 198 participants Est. completion 2028-08-20 1 site Stand-alone

Other conditions: IgG4 Related Disease
View official trial listing →
Recruiting NCT NCT07126236

Response-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Efficacy of Eptoritamab in Patients With Relapse/Refractory Large B Cell Lymphoma

Not yet reported Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea 80 participants Est. completion 2031-12 15 sites Stand-alone

Other conditions: Large B Cell Lymphoma
View official trial listing →
Recruiting NCT NCT07149857

A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel

Not yet reported Janssen Research & Development, LLC 60 participants Est. completion 2029-04-06 17 sites Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Recruiting NCT NCT07285239

Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma

Not yet reported PrECOG, LLC. 500 participants Est. completion 2034-06 1 site Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Recruiting NCT NCT07418190

Efficacy and Safety of Zanubrutinib, Rituximab, and Lenalidomide (ZR²) in Combination With Tislelizumab for Relapsed/Refractory Follicular Lymphoma

Not yet reported The First Affiliated Hospital with Nanjing Medical University 33 participants Est. completion 2029-12-31 1 site Stand-alone

Other conditions: Relapsed/Refractory Follicular Lymphoma
View official trial listing →
Recruiting NCT NCT07448324

Orelabrutinib Combined With Rituximab ± Lenalidomide in Response-Adapted Stratified Therapy for Untreated MZL

Not yet reported The First Affiliated Hospital with Nanjing Medical University 50 participants Est. completion 2030-01-01 1 site Stand-alone

Other conditions: Marginal Zone Lymphoma(MZL)
View official trial listing →
Recruiting NCT NCT07452198

A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma

Not yet reported Genrix (Shanghai) Biopharmaceutical Co., Ltd. 358 participants Est. completion 2030-03 1 site

Other conditions: Multiple Myeloma
View official trial listing →
Recruiting NCT NCT07477587

A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma

Not yet reported Shanghai Henlius Biotech 258 participants Est. completion 2028-02-22 81 sites

Other conditions: Multiple Myeloma (MM)
View official trial listing →
Recruiting NCT NCT07485647

Identifying Effective and Cost-Conscious Maintenance Daratumumab Dosing

Not yet reported Eden Biltibo 50 participants Est. completion 2029-04 1 site Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Recruiting NCT NCT07518186

A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

Not yet reported Janssen Research & Development, LLC 700 participants Est. completion 2032-12-08 151 sites

Other conditions: Multiple Myeloma
View official trial listing →
Completed NCT NCT00031941

CC-5013 in Treating Patients With Cancer That Has Not Responded to Previous Therapy

Not yet reported National Institutes of Health Clinical Center (CC) Est. completion 2009-04 2 sites

Other conditions: Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
View official trial listing →
Completed NCT NCT00036894

CC-5013 in Treating Patients With Recurrent Glioma

Not yet reported National Cancer Institute (NCI) 1 site

Other conditions: Brain and Central Nervous System Tumors
View official trial listing →
Completed NCT NCT00056160

CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma

Not yet reported Celgene 353 participants Est. completion 2008-10-01 49 sites Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Completed NCT NCT00064038

S0232 Dexamethasone With or Without Lenalidomide in Treating Patients With Previously Untreated Stage I, Stage II, or Stage III Multiple Myeloma

Not yet reported SWOG Cancer Research Network 198 participants Est. completion 2012-05 2 sites Stand-alone

Other conditions: Multiple Myeloma, Plasma Cell Neoplasm
View official trial listing →
Completed NCT NCT00064974

Efficacy and Safety Study of CC-5013 Monotherapy in Subjects With Myelodysplastic Syndromes

Not yet reported Celgene Corporation 215 participants Est. completion 2007-02 119 sites

Other conditions: Myelodysplastic Syndromes
View official trial listing →
Completed NCT NCT00065351

Safety and Efficacy of Single-agent CC-5013 in Subjects With Relapsed and Refractory Multiple Myeloma

Not yet reported Celgene 222 participants Est. completion 2007-03-01 26 sites

Other conditions: Multiple Myeloma
View official trial listing →
Completed NCT NCT00091260

CC-5013 With or Without Dexamethasone in Treating Patients With Primary Systemic Amyloidosis

Not yet reported Vaishali Sanchorawala 82 participants Est. completion 2015-05 1 site Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Completed NCT NCT00091624

A Study of Doxil, Vincristine and Decadron (DVd) +/ CC-5013 in Relapsed Refractory Multiple Myeloma (MM)

Not yet reported Celgene Corporation 77 participants Est. completion 2007-09 1 site

Other conditions: Multiple Myeloma
View official trial listing →
Active, not recruiting NCT NCT00098475

Lenalidomide and Dexamethasone With or Without Thalidomide in Treating Patients With Multiple Myeloma

Not yet reported National Cancer Institute (NCI) 452 participants Est. completion 2026-10-23 138 sites Stand-alone

Other conditions: DS Stage I Multiple Myeloma, DS Stage II Multiple Myeloma, DS Stage III Multiple Myeloma
View official trial listing →
Completed NCT NCT00100880

Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors

Not yet reported National Cancer Institute (NCI) 45 participants 1 site Stand-alone

Other conditions: Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Germ Cell Tumor, Childhood Choroid Plexus Tumor, Childhood Craniopharyngioma, Childhood Ependymoblastoma, Childhood Grade I Meningioma, Childhood Grade II Meningioma, Childhood Grade III Meningioma, Childhood High-grade Cerebellar Astrocytoma, Childhood High-grade Cerebral Astrocytoma, Childhood Infratentorial Ependymoma, Childhood Low-grade Cerebellar Astrocytoma, Childhood Low-grade Cerebral Astrocytoma, Childhood Medulloepithelioma, Childhood Mixed Glioma, Childhood Oligodendroglioma, Childhood Supratentorial Ependymoma, Recurrent Childhood Brain Tumor, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma, Recurrent Childhood Medulloblastoma, Recurrent Childhood Pineoblastoma, Recurrent Childhood Subependymal Giant Cell Astrocytoma, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor, Recurrent Childhood Visual Pathway and Hypothalamic Glioma
View official trial listing →
Completed NCT NCT00104962

Lenalidomide in Treating Young Patients With Relapsed or Refractory Solid Tumors or Myelodysplastic Syndromes

Not yet reported National Cancer Institute (NCI) 24 participants Est. completion 2009-06 1 site Stand-alone

Other conditions: Childhood Myelodysplastic Syndromes, de Novo Myelodysplastic Syndromes, Previously Treated Myelodysplastic Syndromes, Refractory Anemia, Refractory Anemia With Excess Blasts, Refractory Anemia With Ringed Sideroblasts, Refractory Cytopenia With Multilineage Dysplasia, Secondary Myelodysplastic Syndromes, Unspecified Childhood Solid Tumor, Protocol Specific
View official trial listing →
Completed NCT NCT00109005

Lenalidomide (Revlimid) to Treat Advanced Ocular Melanoma

Not yet reported National Cancer Institute (NCI) 17 participants Est. completion 2009-04 1 site Stand-alone

Other conditions: Melanoma
View official trial listing →
Terminated NCT NCT00109772

Study to Evaluate the Efficacy and Safety of Lenalidomide in the Treatment of Complex Regional Pain Syndrome Type 1

Not yet reported Celgene Corporation 184 participants Est. completion 2008-04 27 sites Stand-alone

Other conditions: Complex Regional Pain Syndrome, Type I
View official trial listing →
Completed NCT NCT00151203

Phase II Study of Biaxin, Revlimid, and Dexamethasone for Untreated Multiple Myeloma

Not yet reported Weill Medical College of Cornell University 50 participants Est. completion 2020-09-29 1 site

Other conditions: Multiple Myeloma
View official trial listing →
Completed NCT NCT00179608

Study of the Combination of Lenalidomide and DTIC (Dacarbazine) in Patients With Metastatic Malignant Melanoma Previously Untreated With Systemic Chemotherapy

Not yet reported Celgene 28 participants Est. completion 2007-06-01 1 site

Other conditions: Malignant Melanoma
View official trial listing →
Completed NCT NCT00179647

Expanded Access Program:Lenalidomide With or Without Dexamethasone In Previously Treated Subjects With Multiple Myeloma

Not yet reported Celgene Corporation 1913 participants Est. completion 2009-04 69 sites

Other conditions: Multiple Myeloma
View official trial listing →
Completed NCT NCT00179660

Safety And Efficacy Of Lenalidomide In Patients With Relapsed Or Refractory Aggressive Non-Hodgkin's Lymphoma (NHL)

Not yet reported Celgene Corporation 50 participants Est. completion 2008-06 8 sites Stand-alone

Other conditions: Non-Hodgkins Lymphoma
View official trial listing →
Completed NCT NCT00179686

A Study to Evaluate the Single-Agent Lenalidomide in Subjects With Recurrent Non-Small-Cell Lung Cancer

Not yet reported Celgene Corporation 40 participants Est. completion 2006-07 6 sites

Other conditions: Non-Small Cell Lung Cancer
View official trial listing →
Terminated NCT NCT00179738

A Multicenter, Single-Arm, Open-Label, Study to Evaluate the Safety and Efficacy of Single-Agent Lenalidomide (Revlimid, CC-5013) in Subjects With Androgen Independent Prostate Cancer.

Not yet reported Celgene Corporation 40 participants Est. completion 2007-04 6 sites

Other conditions: Prostate Cancer
View official trial listing →
Terminated NCT NCT00179751

A Phase I/II Study of Lenalidomide in Combination With Gemcitabine in Patients With Untreated Advanced Carcinoma of the Pancreas

Not yet reported, Not yet reported Celgene Corporation 50 participants Est. completion 2006-08 6 sites

Other conditions: Pancreatic Cancer
View official trial listing →
Completed NCT NCT00253344

Lenalidomide and Docetaxel in Treating Patients With Advanced Solid Tumors

Not yet reported Case Comprehensive Cancer Center 33 participants Est. completion 2008-06 1 site

Other conditions: Unspecified Adult Solid Tumor, Protocol Specific
View official trial listing →
Completed NCT NCT00267059

Lenalidomide (Revlimid) in Chronic Lymphocytic Leukemia (CLL)

Not yet reported M.D. Anderson Cancer Center 45 participants Est. completion 2009-08 1 site Stand-alone

Other conditions: Chronic Lymphocytic Leukemia, Leukemia
View official trial listing →
Completed NCT NCT00305812

Lenalidomide and Melphalan in Treating Patients With Previously Untreated Multiple Myeloma

Not yet reported NCIC Clinical Trials Group 51 participants Est. completion 2008-06-30 14 sites

Other conditions: Multiple Myeloma and Plasma Cell Neoplasm
View official trial listing →
Completed NCT NCT00306813

Evaluation of Lenalidomide, Doxorubicin and Dexamethasone (RAD) in Patients With Relapsed or Refractory Multiple Myeloma

Not yet reported, Not yet reported University of Wuerzburg 53 participants Est. completion 2008-12 1 site

Other conditions: Relapse, Refractory Multiple Myeloma
View official trial listing →
Completed NCT NCT00348595

Study of 2 Different Doses of Revlimid in Biochemically Relapse Prostate Cancer

Not yet reported, Not yet reported Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 77 participants Est. completion 2016-06-29 1 site

Other conditions: Prostate Cancer
View official trial listing →
Completed NCT NCT00352001

Lenalidomide and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndromes

Not yet reported, Not yet reported Mikkael Sekeres MD 37 participants Est. completion 2011-09 3 sites Stand-alone

Other conditions: Leukemia, Myelodysplastic Syndromes
View official trial listing →
Completed NCT NCT00352365

Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia

Not yet reported National Cancer Institute (NCI) 41 participants Est. completion 2011-07-01 54 sites Stand-alone

Other conditions: Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Secondary Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
View official trial listing →
Completed NCT NCT00360672

Revlimid in Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome

Not yet reported M.D. Anderson Cancer Center 27 participants Est. completion 2012-05 1 site

Other conditions: Acute Myelogenous Leukemia, Myelodysplastic Syndrome
View official trial listing →
Completed NCT NCT00378209

Bortezomib, Lenalidomide, and Dexamethasone Combination Therapy for Patients With Relapsed or Relapsed and Refractory Multiple Myeloma

Not yet reported Dana-Farber Cancer Institute 65 participants Est. completion 2016-10 2 sites Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Completed NCT NCT00405756

A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older.

Not yet reported Celgene Corporation 459 participants Est. completion 2016-04 98 sites Stand-alone

Other conditions: Newly Diagnosed Multiple Myeloma
View official trial listing →
Completed NCT NCT00412581

Lenalidomide and Dacarbazine (DTIC) in Patients With Metastatic Melanoma

Not yet reported M.D. Anderson Cancer Center 28 participants Est. completion 2008-03 1 site Stand-alone

Other conditions: Melanoma
View official trial listing →
Completed NCT NCT00415064

Phase I Study of Perifosine + Lenalidomide and Dexamethasone for Patients With Multiple Myeloma

Not yet reported AEterna Zentaris 32 participants Est. completion 2012-07 1 site

Other conditions: Multiple Myeloma
View official trial listing →
Completed NCT NCT00418665

A Safety and Efficacy Study to Evaluate AMG 531 Treatment in Subject With Myelodysplastic Syndrome Receiving Revlimid

Not yet reported Amgen 39 participants Est. completion 2010-10

Other conditions: Myelodysplastic Syndromes, Thrombocytopenia
View official trial listing →
Status unknown NCT NCT00424229

Lenalidomide in Subjects With intermediate2 or High MDS Associated With a Deletion (DEL) 5q [31]

Not yet reported Groupe Francophone des Myelodysplasies 49 participants Est. completion 2008-10 11 sites

Other conditions: Myelodysplastic Syndromes
View official trial listing →
Status unknown NCT NCT00434239

Lenalidomide and Recombinant Human Stem Cell Factor for Treatment of Myelodysplasia

Not yet reported Peter MacCallum Cancer Centre, Australia 25 participants Est. completion 2014-05 1 site Stand-alone

Other conditions: Myelodysplasia
View official trial listing →
Completed NCT NCT00439231

Lenalidomide in Previously Treated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Not yet reported Georg Aue, M.D. 33 participants Est. completion 2010-11 1 site Stand-alone

Other conditions: Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma
View official trial listing →
Completed NCT NCT00445484

Lenalidomide and Vaccine Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma

Not yet reported Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 22 participants Est. completion 2010-09 1 site Stand-alone

Other conditions: Multiple Myeloma and Plasma Cell Neoplasm
View official trial listing →
Completed NCT NCT00446433

A Study to Evaluate CC-5013 in the Treatment of Adolescents and Adults With Moderately Severe Crohn's Disease

Not yet reported Celgene Corporation 90 participants Est. completion 2003-12 20 sites

Other conditions: Crohn's Disease
View official trial listing →
Completed NCT NCT00466895

Lenalidomide in Acute Leukemias and Chronic Lymphocytic Leukemia.

Not yet reported Leslie Andritsos 37 participants Est. completion 2016-07 1 site Stand-alone

Other conditions: Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia
View official trial listing →
Completed NCT NCT00466921

Lenalidomide in Treating Patients With Relapsed Mycosis Fungoides/Sezary Syndrome

Not yet reported Northwestern University 33 participants Est. completion 2013-05-17 3 sites Stand-alone

Other conditions: Lymphoma
View official trial listing →
Completed NCT NCT00477750

Melphalan, Prednisone, and Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma

Not yet reported, Not yet reported Mayo Clinic 33 participants Est. completion 2013-08-05 3 sites Stand-alone

Other conditions: Multiple Myeloma and Plasma Cell Neoplasm
View official trial listing →
Completed NCT NCT00478959

Phase II Study of Lenalidomide for the Treatment of Relapsed or Refractory Hodgkin's Lymphoma

Not yet reported University Health Network, Toronto 30 participants Est. completion 2014-06 Stand-alone

Other conditions: Hodgkin Disease
View official trial listing →
Completed NCT NCT00482261

A Study of Low Dose Lenalidomide and Dexamethasone in Relapsed/Refractory Myeloma in Patients at High Risk for Myelosuppression

Not yet reported Peter MacCallum Cancer Centre, Australia 150 participants Est. completion 2014-02 1 site Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Terminated NCT NCT00482911

Lenalidomide, Sunitinib, and Cyclophosphamide in Treating Patients With Stage IV Eye Melanoma

Not yet reported National Institutes of Health Clinical Center (CC) 12 participants Est. completion 2009-04 1 site Stand-alone

Other conditions: Intraocular Melanoma, Malignant Conjunctival Neoplasm
View official trial listing →
Terminated NCT NCT00522392

Bortezomib and Dexamethasone With or Without Lenalidomide in Treating Patients With Multiple Myeloma Previously Treated With Dexamethasone

Not yet reported National Cancer Institute (NCI) 48 participants Est. completion 2014-07 276 sites Stand-alone

Other conditions: Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
View official trial listing →
Completed NCT NCT00540007

Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma

Not yet reported Washington University School of Medicine 80 participants Est. completion 2016-09-01 5 sites Stand-alone

Other conditions: Hodgkin Disease
View official trial listing →
Completed NCT NCT00555100

Safety Study of Lenalidomide With and Without Dexamethasone in Japanese Subjects With Previously Treated Multiple Myeloma

Not yet reported Celgene 15 participants Est. completion 2010-12-01 5 sites

Other conditions: Multiple Myeloma
View official trial listing →
Completed NCT NCT00602459

Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia

Not yet reported National Cancer Institute (NCI) 418 participants Est. completion 2023-04-15 364 sites Stand-alone

Other conditions: Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia, Stage IV Chronic Lymphocytic Leukemia
View official trial listing →
Completed NCT NCT00602836

Rituximab, Pentostatin, Cyclophosphamide, and Lenalidomide in Treating Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Not yet reported Mayo Clinic 45 participants Est. completion 2017-09-12 3 sites Stand-alone

Other conditions: Leukemia, Lymphoma
View official trial listing →
Completed NCT NCT00607581

Cyclophosphamide, Lenalidomide and Dexamethasone (CLD) for Previously Treated Patients With AL Amyloidosis

Not yet reported Fondazione IRCCS Policlinico San Matteo di Pavia 21 participants Est. completion 2012-01 1 site Stand-alone

Other conditions: Amyloidosis
View official trial listing →
Completed NCT NCT00617591

Pegylated Liposomal Doxorubicin, Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM)

Not yet reported H. Lee Moffitt Cancer Center and Research Institute 57 participants Est. completion 2013-04 1 site Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Completed NCT NCT00633945

Evaluation of Lenalidomide (REVLIMID®) to Treat Subjects With Cutaneous Lupus Erythematosus (CLE)

Not yet reported University of Pennsylvania 5 participants Est. completion 2009-10 1 site Stand-alone

Other conditions: Cutaneous Lupus Erythematosus (CLE)
View official trial listing →
Completed NCT NCT00642954

Vorinostat (MK-0683, SAHA [Suberoylanilide Hydroxamic Acid]) + Lenalidomide + Dexamethasone in Multiple Myeloma (MM) (MK-0683-074)

Not yet reported Merck Sharp & Dohme LLC 31 participants Est. completion 2013-08-20 Stand-alone

Other conditions: Relapsed or Refractory Multiple Myeloma
View official trial listing →
Terminated NCT NCT00665652

Study of Lenalidomide as a Treatment for Neuropathy Associated With Monoclonal Gammopathy of Undetermined Significance

Not yet reported Dartmouth-Hitchcock Medical Center 8 participants Est. completion 2011-05-19 1 site Stand-alone

Other conditions: Neuropathy, Nonmalignant Monoclonal Gammopathy of Undetermined Significance (MGUS)
View official trial listing →
Terminated NCT NCT00671801

Irinotecan Plus Lenalidomide in Adult Patients With Recurrent Glioblastoma Multiforme: Phase I

Not yet reported M.D. Anderson Cancer Center 24 participants Est. completion 2014-02 1 site Stand-alone

Other conditions: Malignant Gliomas
View official trial listing →
Completed NCT NCT00679367

Melphalan, Lenalidomide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis

Not yet reported Boston Medical Center 16 participants Est. completion 2015-05 1 site Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Terminated NCT NCT00684242

Lenalidomide (Revlimid) for the Treatment of Refractory Cancer Pain

Not yet reported M.D. Anderson Cancer Center 4 participants Est. completion 2011-10 1 site Stand-alone

Other conditions: Advanced Cancer, Pain
View official trial listing →
Terminated NCT NCT00687674

Sorafenib, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Not yet reported Mayo Clinic 13 participants Est. completion 2011-11 1 site Stand-alone

Other conditions: Multiple Myeloma and Plasma Cell Neoplasm
View official trial listing →
Completed NCT NCT00689936

Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma

Not yet reported Celgene 1623 participants Est. completion 2016-07-14 288 sites Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Completed NCT NCT00744536

Efficacy Study of Revlimid® and Low Dose Continuously Administered Melphalan to Treat High Risk MDS

Not yet reported Sunnybrook Health Sciences Centre 20 participants Est. completion 2012-12 1 site Stand-alone

Other conditions: Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic, Angiogenesis
View official trial listing →
Completed NCT NCT00784927

Lenalidomide, Rituximab, Cyclophosphamide, and Dexamethasone in Treating Patients With Previously Untreated Low-Grade Non-Hodgkin Lymphoma

Not yet reported Mayo Clinic 36 participants Est. completion 2016-02 2 sites Stand-alone

Other conditions: Lymphoma
View official trial listing →
Terminated NCT NCT00790842

Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction

Not yet reported, Not yet reported PrECOG, LLC. 63 participants Est. completion 2018-03-08 16 sites Stand-alone

Other conditions: Multiple Myeloma, Plasma Cell Neoplasm
View official trial listing →
Completed NCT NCT00792077

A Pilot Study to Investigate the Effect of Cytotoxic Therapy and/or Radiotherapy on Cancer Related Sleep Disturbances in CLL and Breast Cancer Patients Experiencing Fatigue

Not yet reported M.D. Anderson Cancer Center 6 participants Est. completion 2020-08-03 1 site Stand-alone

Other conditions: Leukemia, CLL
View official trial listing →
Completed NCT NCT00799513

Trial on Lenalidomide Given as Maintenance Therapy for Relapsed Diffuse Large B Cell Lymphoma

Not yet reported IRCCS San Raffaele 48 participants Est. completion 2021-08 1 site Stand-alone

Other conditions: Diffuse Large B-cell Lymphoma
View official trial listing →
Completed NCT NCT00807599

Lenalidomide (Revlimid®) Plus Low-dose Dexamethasone (Ld x 4 Cycles) Then Stem Cell Collection Followed by Randomization to Continued Ld or Stem Cell Transplantation (SCT) Plus Maintenance L

Not yet reported Memorial Sloan Kettering Cancer Center 67 participants Est. completion 2018-07 7 sites Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Completed NCT NCT00812968

Study of CC-5013 to Evaluate Safety, Pharmacokinetics and Effectiveness for Japanese Patients With Symptomatic Anemia Associated With Myelodysplastic Syndrome With a Del(5)(q31-33) Abnormality.

Not yet reported Celgene 11 participants Est. completion 2010-09-01 6 sites Stand-alone

Other conditions: Myelodysplastic Syndromes
View official trial listing →
Withdrawn NCT NCT00829647

A Study Using Two Oral Chemotherapy Agents for Chronic Lymphocytic Leukemia

Not yet reported, Not yet reported Scripps Health Est. completion 2016-03-01 Stand-alone

Other conditions: Chronic Lymphocytic Leukemia, Leukemia
View official trial listing →
Completed NCT NCT00833833

MTD, Safety, and Efficacy of Pomalidomide (CC-4047) Alone or With Low-dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma

Not yet reported, Not yet reported Celgene Corporation 259 participants Est. completion 2015-09 19 sites

Other conditions: Multiple Myeloma
View official trial listing →
Terminated NCT NCT00843310

Combination of Revlimid, Melphalan and Dexamethasone as First Line Treatment for Multiple Myeloma

Not yet reported NYU Langone Health 8 participants Est. completion 2011-10 3 sites Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Completed NCT NCT00864942

Trial of Bendamustine, Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL)

Not yet reported Georgetown University 28 participants Est. completion 2014-10 1 site Stand-alone

Other conditions: Chronic Lymphocytic Leukemia, Non-Hodgkin's Lymphoma
View official trial listing →
Completed NCT NCT00874978

The Efficacy and Safety of Lenalidomide Monotherapy in Red Blood Cell Transfusion Dependent Subjects With Myelodysplastic Syndrome (MDS) Associated With Del (5q) Abnormality

Not yet reported King's College Hospital NHS Trust 36 participants Est. completion 2016-05 1 site Stand-alone

Other conditions: Myelodysplastic Syndromes
View official trial listing →
Completed NCT NCT00884546

Multiple Ascending Dose (MAD) Combination in Subjects With Multiple Myeloma

Not yet reported Bristol-Myers Squibb 27 participants Est. completion 2012-03 8 sites

Other conditions: Advanced Cancer, Various, NOS
View official trial listing →
Status unknown NCT NCT00885508

A Study of the Efficacy and Safety of Lenalidomide Combined to Escalating Doses of Chemotherapy in Intermediate-2-or High Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) With Del 5q

Not yet reported Groupe Francophone des Myelodysplasies 85 participants Est. completion 2015-12 25 sites Stand-alone

Other conditions: Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, Acute Myeloid Leukemia
View official trial listing →
Completed NCT NCT00890929

Phase 1-2 of Azacitidine + Lenalidomide for Previously Untreated Elderly Patients With Acute Myeloid Leukemia (AML)

Not yet reported, Not yet reported Stanford University 45 participants Est. completion 2012-06 1 site Stand-alone

Other conditions: Acute Myeloid Leukemia (AML), Adult Acute Myeloblastic Leukemia
View official trial listing →
Completed NCT NCT00891384

Comparison of 25mg Versus 5 mg Lenalidomide as Maintenance Therapy in Patients With Multiple Myeloma

Not yet reported Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH 194 participants Est. completion 2017-06-22 5 sites Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Completed NCT NCT00901615

Lenalidomide and R-CHOP in B-cell Lymphoma

Not yet reported, Not yet reported Lymphoma Study Association 108 participants Est. completion 2015-11-23 5 sites Stand-alone

Other conditions: Lymphoma, Large B-Cell, Diffuse, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma
View official trial listing →
Status unknown NCT NCT00902915

Lenalidomide and Dexamethasone for Treatment of Patients With Acute Myeloma (Light Chain)-Induced Renal Failure

Not yet reported Austrian Forum Against Cancer 50 participants Est. completion 2014-05 5 sites Stand-alone

Other conditions: Multiple Myeloma Light Chain Induced Renal Insufficiency
View official trial listing →
Completed NCT NCT00907452

Pharmacogenomic Study in Myeloma Patients Treated With Melphalan-prednisone-thalidomide or Lenalidomide-dexamethasone

Not yet reported Intergroupe Francophone du Myelome 143 participants Est. completion 2016-07-14 26 sites

Other conditions: Myeloma
View official trial listing →
Completed NCT NCT00908232

Treatment With Velcade (Bortezomib) Plus Dexamethasone (VD) or VD Plus Cyclophosphamide or VD Plus Lenalidomide in Patients With Multiple Myeloma Stabilized After 4 Cycles of VD

Not yet reported Janssen-Cilag International NV 163 participants Est. completion 2011-08 42 sites Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Completed NCT NCT00910858

A Pharmacokinetic And Pharmacodynamic Study Of Oral Lenalidomide (Revlimid) In Subjects With Low- Or Intermediate-1-Risk Myelodysplastic Syndromes

Not yet reported, Not yet reported Celgene Corporation 40 participants Est. completion 2009-05 1 site Stand-alone

Other conditions: Low- or Intermediate-1-risk Myelodysplastic Syndrome (MDS)
View official trial listing →
Completed NCT NCT00910910

Study Of The Effectiveness & Safety Of Lenalidomide Versus Chlorambucil As First Line Therapy For Elderly Patients With B-Cell CLL (The ORIGIN Trial)

Not yet reported Celgene 450 participants Est. completion 2018-05-09 165 sites Stand-alone

Other conditions: B-Cell Chronic Lymphocytic Leukemia
View official trial listing →
Completed NCT NCT00911105

Non -Interventional Study-Palliative Therapy of Multiple Myeloma With a Combination of Lenalidomide and Dexamethasone

iOMEDICO AG 101 participants Est. completion 2015-11 20 sites

Other conditions: Multiple Myeloma
View official trial listing →
Terminated NCT NCT00923234

Combination of 5-azacitidine and Lenalidomide in Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) Myelodysplastic Syndromes

Not yet reported Technische Universität Dresden Est. completion 2012-07 4 sites Stand-alone

Other conditions: Myelodysplastic Syndromes, Acute Myelogenous Leukemia
View official trial listing →
Completed NCT NCT00932698

Study of Oral Ixazomib in Adult Participants With Relapsed and/or Refractory (RR) Multiple Myeloma

Not yet reported Millennium Pharmaceuticals, Inc. 60 participants Est. completion 2017-05-23 5 sites Stand-alone

Other conditions: Relapsed and Refractory Multiple Myeloma
View official trial listing →
Completed NCT NCT00963534

Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma.

Not yet reported, Not yet reported Lund University Hospital 51 participants Est. completion 2017-08 17 sites Stand-alone

Other conditions: Mantle Cell Lymphoma
View official trial listing →
Completed NCT NCT00966693

Lenalidomide, Thalidomide and Dexamethasone in Treating Participants With Relapsed or Refractory Multiple Myeloma

Not yet reported, Not yet reported M.D. Anderson Cancer Center 77 participants Est. completion 2018-07-20 1 site Stand-alone

Other conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
View official trial listing →
Status unknown NCT NCT00971685

The Treatment of Lenalidomide in Patients With POEMS Syndrome

Not yet reported Istituto Clinico Humanitas 16 participants Est. completion 2011-07 1 site Stand-alone

Other conditions: POEMS Syndrome
View official trial listing →
Terminated NCT NCT00972842

Lenalidomide, Vorinostat and Dexamethasone in Relapsed Patients With Peripheral T-Cell Non-Hodgkin's Lymphoma (PTCL)

Not yet reported, Not yet reported Arbeitsgemeinschaft medikamentoese Tumortherapie 20 participants Est. completion 2012-07 5 sites

Other conditions: Peripheral T-Cell Non-Hodgkin's Lymphoma
View official trial listing →
Terminated NCT NCT00975806

Study of Lenalidomide in Combination With Sunitinib to Evaluate the Safety and Efficacy in Patients With Renal Cell Carcinoma

Not yet reported, Not yet reported Celgene 16 participants Est. completion 2011-10-01 3 sites Stand-alone

Other conditions: Renal Cell Carcinoma
View official trial listing →
Terminated NCT NCT00977132

Efficacy and Tolerability of the Combination of Valproic Acid and Lenalidomide in the Treatment of Patients With Myelodysplastic Syndrome

Not yet reported Heinrich-Heine University, Duesseldorf 23 participants Est. completion 2014-05 6 sites Stand-alone

Other conditions: Myelodysplastic Syndrome MDS
View official trial listing →
Completed NCT NCT00991562

IMGN901 in Combination With Lenalidomide and Dexamethasone

Not yet reported ImmunoGen, Inc. 50 participants Est. completion 2014-10 9 sites

Other conditions: Multiple Myeloma
View official trial listing →
Status unknown NCT NCT01002703

Treatment With Lenalidomide, Bendamustine and Prednisone (RBP) in Patients With Relapsed or Refractory Multiple Myeloma

Not yet reported, Not yet reported University of Leipzig 50 participants Est. completion 2014-10 1 site Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Terminated NCT NCT01003769

Lenalidomide and AT-101 in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia

Not yet reported, Not yet reported Mayo Clinic 5 participants Est. completion 2018-12-14 2 sites Stand-alone

Other conditions: Recurrent Chronic Lymphocytic Leukemia
View official trial listing →
Terminated NCT NCT01005979

A Phase I Trial Using Cyclophosphamide, Rituximab and Revlimid (CR2) for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Small Lymphocytic Lymphoma (SLL)

Not yet reported Emory University 6 participants 1 site Stand-alone

Other conditions: Leukemia, Lymphocytic, Chronic, B-Cell, Chronic Lymphocytic Leukemia, Lymphoma, Small Lymphocytic
View official trial listing →
Completed NCT NCT01011894

Lenalidomide in Patients With Chronic Lymphocytic Leukemia Older Than 65 Years of Age

Not yet reported Memorial Sloan Kettering Cancer Center 26 participants Est. completion 2016-02-23 1 site Stand-alone

Other conditions: Chronic Lymphocytic Leukemia, Leukemia
View official trial listing →
Completed NCT NCT01029054

Carfilzomib and Lenalidomide With Dexamethasone Combination in Newly Diagnosed, Previously Untreated Multiple Myeloma

Not yet reported, Not yet reported University of Michigan Rogel Cancer Center 53 participants Est. completion 2015-07 4 sites Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Terminated NCT NCT01032291

A Study to Assess the Efficacy and Safety of Lenalidomide in Combination With Cetuximab in Pre-treated Patients With KRAS Mutant Colorectal Cancer

Not yet reported Celgene Corporation 51 participants Est. completion 2011-01 17 sites Stand-alone

Other conditions: Colorectal Cancer
View official trial listing →
Terminated NCT NCT01034592

Pilot Lenalidomide in Adult Diamond-Blackfan Anemia Patients w/ RBC Transfusion-Dependent Anemia

Not yet reported Jason Robert Gotlib 2 participants Est. completion 2012-12 1 site Stand-alone

Other conditions: Anemia, Leukemia, Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)
View official trial listing →
Completed NCT NCT01038388

A Study of the Combination Vorinostat With Lenalidomide, Bortezomib and Dexamethasone for Patients With Newly Diagnosed Multiple Myeloma

Not yet reported Emory University 30 participants Est. completion 2021-08-05 1 site Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Completed NCT NCT01049945

Bendamustine Hydrochloride, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

Not yet reported, Not yet reported Mayo Clinic 70 participants Est. completion 2015-09-16 5 sites Stand-alone

Other conditions: Refractory Multiple Myeloma
View official trial listing →
Status unknown NCT NCT01053806

Safety And Efficacy Of Azacitidine, and Lenalidomide In Higher Risk Myelodysplastic Syndrome

Not yet reported Tel-Aviv Sourasky Medical Center 6 participants 1 site

Other conditions: Myelodysplastic Syndrome
View official trial listing →
Completed NCT NCT01053949

IFM2009-02-Pomalidomide and Dexamethasone Phase 2 Myeloma

Not yet reported University Hospital, Lille 84 participants Est. completion 2015-04 19 sites

Other conditions: Multiple Myeloma
View official trial listing →
Completed NCT NCT01062152

Dose-Ranging Study of Telintra® Tablets + Revlimid® in Patients With Non-Deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Not yet reported Telik 19 participants Est. completion 2013-03 9 sites Stand-alone

Other conditions: Myelodysplastic Syndrome
View official trial listing →
Completed NCT NCT01080391

Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma

Not yet reported Amgen 792 participants Est. completion 2017-12-05 127 sites Stand-alone

Other conditions: Relapsed Multiple Myeloma
View official trial listing →
Completed NCT NCT01088373

Lenalidomide Combined to Azacitidine in Intermediate-2 or High Risk MDS With Del 5q

Not yet reported Groupe Francophone des Myelodysplasies 50 participants Est. completion 2016-07-25 34 sites Stand-alone

Other conditions: Myelodysplastic Syndromes
View official trial listing →
Completed NCT NCT01090089

Combination of Lenalidomide and Dexamethasone in Treatment of Multiple Myeloma

Not yet reported Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH 348 participants Est. completion 2020-01-31 31 sites Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Completed NCT NCT01099267

Multi-center, Survival Data Collection in Subjects Previously Enrolled in Celgene Protocol CC-5013-MDS-003

Celgene 54 participants Est. completion 2010-10-01 15 sites

Other conditions: Myelodysplastic Syndrome
View official trial listing →
Completed NCT NCT01116193

Repeat-dose Study of Lenalidomide (Revlimid ®) Plus Dexamethasone in Patients With Lymphoblastic Leukemia

Not yet reported Institut de Cancérologie de la Loire 10 participants Est. completion 2013-08 4 sites

Other conditions: Leukemia, Lymphoid, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
View official trial listing →
Terminated NCT NCT01121757

Epigenetic Modulation in Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma

Not yet reported Duke University 11 participants Est. completion 2016-01 1 site Stand-alone

Other conditions: Follicular Lymphoma, Marginal Zone Lymphoma
View official trial listing →
Completed NCT NCT01125176

Alternating Thalidomide and Lenalidomide Therapy Plus Rituximab (ThRiL) as Initial Treatment for Patients With CLL

Not yet reported Weill Medical College of Cornell University 15 participants Est. completion 2020-12-29 1 site Stand-alone

Other conditions: Chronic Lymphocytic Leukemia
View official trial listing →
Terminated NCT NCT01127542

RESPeCT: Revlimid Early Stage Poor Prognosis Chronic Lymphocytic Leukaemia (CLL) Trial

Not yet reported The Christie NHS Foundation Trust 1 participants Est. completion 2011-12 9 sites Stand-alone

Other conditions: Chronic Lymphocytic Leukaemia
View official trial listing →
Completed NCT NCT01142232

Lenalidomide and High Dose Melphalan Followed by Autologous Stem Cell Transplant in Multiple Myeloma

Not yet reported, Not yet reported Attaya Suvannasankha 60 participants Est. completion 2019-05-18 1 site Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Status unknown NCT NCT01155505

Lenalidomide and Paclitaxel in Advanced Solid Tumors

Not yet reported Southern Europe New Drug Organization 28 participants Est. completion 2012-03 2 sites Stand-alone

Other conditions: Advanced Solid Tumors
View official trial listing →
Completed NCT NCT01166113

Pomalidomide, Cyclophosphamide and Prednisone (PCP) in Patients With Multiple Myeloma (MM) Relapsed and/or Refractory to Lenalidomide

Not yet reported, Not yet reported Fondazione EMN Italy Onlus 67 participants Est. completion 2023-06 1 site Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Completed NCT NCT01169298

A Phase I, Multicenter, Open-label, Dose-escalation Study to Assess the Safety of Lenalidomide in Patients With Advanced Adult T-cell Leukemia-lymphoma and Peripheral T-cell Lymphomaperipheral T-cell Lymphoma

Not yet reported Celgene 13 participants Est. completion 2013-12-20 6 sites Stand-alone

Other conditions: Adult T-cell Leukemia-Lymphoma, Peripheral T-cell Lymphoma
View official trial listing →
Completed NCT NCT01178814

Revlimid in Transfusion Dependent Patients

Not yet reported Columbia University 57 participants Est. completion 2022-12-07 1 site Stand-alone

Other conditions: Myelodysplastic Syndrome
View official trial listing →
Withdrawn NCT NCT01180569

Lenalidomide Therapy In Previously Untreated, Advanced Stage Follicular Lymphoma

Not yet reported, Not yet reported Memorial Sloan Kettering Cancer Center Est. completion 2011-05 Stand-alone

Other conditions: Lymphoma, Follicular Lymphoma
View official trial listing →
Completed NCT NCT01185262

Activity & Safety Study of Lenalidomide & Rituximab as Non-chemotherapy Based Therapy on Chronic Lymphocytic Leukemia

Not yet reported MD Anderson International Spain SA 25 participants Est. completion 2013-09 7 sites Stand-alone

Other conditions: Chronic Lymphocytic Leukemia
View official trial listing →
Completed NCT NCT01194791

Lendexal in Patients With Primary Systemic Amyloidosis (AL) Newly Diagnosed

Not yet reported PETHEMA Foundation 30 participants Est. completion 2016-12 10 sites Stand-alone

Other conditions: Primary Systemic Amyloidosis
View official trial listing →
Terminated NCT NCT01198054

LENA-LMA-5:Lenalidomide in Acute Myeloid Leukemia (AML)

Not yet reported PETHEMA Foundation 4 participants Est. completion 2013-02 12 sites Stand-alone

Other conditions: AML
View official trial listing →
Terminated NCT NCT01200004

Study of Grifola Frondosa (Maitake), Azacitidine, and Lenalidomide

Not yet reported M.D. Anderson Cancer Center 1 participants Est. completion 2013-07 1 site Stand-alone

Other conditions: Advanced Cancers
View official trial listing →
Terminated NCT NCT01202890

Study of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian Cancer

Not yet reported New Mexico Cancer Research Alliance 1 participants Est. completion 2012-05 1 site Stand-alone

Other conditions: Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma
View official trial listing →
Completed NCT NCT01207921

Lenalidomide Maintenance Therapy Post Autologous Transplant for Hodgkins Lymphoma

Not yet reported Washington University School of Medicine 28 participants Est. completion 2021-03-05 3 sites Stand-alone

Other conditions: Hodgkin Disease
View official trial listing →
Active, not recruiting NCT NCT01208662

Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65

Not yet reported Paul Richardson, MD 729 participants Est. completion 2026-12 46 sites Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Terminated NCT NCT01222195

Lenalidomide and Darbepoetin in Low-Intermediate Risk Myelodysplastic Syndrome (MDS)

Not yet reported M.D. Anderson Cancer Center 1 participants Est. completion 2010-07 1 site Stand-alone

Other conditions: Leukemia
View official trial listing →
Completed NCT NCT01241292

Japanese Study of BMS-901608 (Elotuzumab) in Combination With Lenalidomide and Low Dose Dexamethasone

Not yet reported Bristol-Myers Squibb 7 participants Est. completion 2017-01-16 3 sites

Other conditions: Multiple Myeloma
View official trial listing →
Completed NCT NCT01241734

Study of Lenalidomide in Combination With RICE With Lenalidomide Maintenance Post-Auto Transplant for DLBCL

Not yet reported, Not yet reported Hackensack Meridian Health 18 participants Est. completion 2015-09-22 2 sites Stand-alone

Other conditions: Diffuse Large B Cell Lymphoma
View official trial listing →
Completed NCT NCT01243944

Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)

Not yet reported Incyte Corporation 222 participants Est. completion 2018-02-09 102 sites

Other conditions: Polycythemia Vera
View official trial listing →
Completed NCT NCT01245673

Combination Immunotherapy and Autologous Stem Cell Transplantation for Myeloma

Not yet reported University of Pennsylvania 28 participants Est. completion 2018-12 2 sites Stand-alone

Other conditions: Myeloma
View official trial listing →
Withdrawn NCT NCT01269203

Efficacy of NF-kB Inhibition for Reducing Symptoms During Maintenance Therapy in Multiple Myeloma Patients

Not yet reported M.D. Anderson Cancer Center

Other conditions: Multiple Myeloma
View official trial listing →
Completed NCT NCT01270932

Lenalidomide & High Dose Dexamethasone for Untreated Multiple Myeloma Renal Failure Patients

Not yet reported University Health Network, Toronto 28 participants Est. completion 2017-12-18 1 site Stand-alone

Other conditions: Renal Failure, Multiple Myeloma
View official trial listing →
Withdrawn NCT NCT01271283

Lenalidomide in Treating Patients With High-Risk Chronic Lymphocytic Leukemia

Not yet reported National Cancer Institute (NCI) Est. completion 2011-08 1 site Stand-alone

Other conditions: Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia, Stage IV Chronic Lymphocytic Leukemia
View official trial listing →
Completed NCT NCT01274533

Lenalidomide in HTLV-1 Adult T-Cell Leukemia

Not yet reported Columbia University 4 participants Est. completion 2013-05 1 site Stand-alone

Other conditions: Adult T Cell Leukemia/Lymphoma
View official trial listing →
Terminated NCT NCT01282047

Lenalidomide in Kaposi Disease Associated With HIV Infection

Not yet reported French National Agency for Research on AIDS and Viral Hepatitis 12 participants Est. completion 2014-02 1 site Stand-alone

Other conditions: HIV Infection Associated Kaposi Disease
View official trial listing →
Active, not recruiting NCT NCT01297764

A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma

Not yet reported, Not yet reported Hackensack Meridian Health 17 participants Est. completion 2027-06 1 site Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Completed NCT NCT01301820

Elderly Patients With Acute Myeloid Leukemia (AML), Maintenance Phase After Complete Remission (CR)

Not yet reported French Innovative Leukemia Organisation 120 participants Est. completion 2013-02 1 site

Other conditions: Acute Myeloid Leukemia
View official trial listing →
Terminated NCT NCT01301963

Filgrastim With or Without Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide

Not yet reported Case Comprehensive Cancer Center 9 participants 2 sites

Other conditions: Refractory Multiple Myeloma
View official trial listing →
Terminated NCT NCT01303965

Allo Transplant Followed by Lenalidomide and Sirolimus Maintenance in High-Risk Multiple Myeloma (MM)

Not yet reported, Not yet reported Sherif S. Farag 14 participants Est. completion 2017-07-28 1 site Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Status unknown NCT NCT01307592

Gemcitabine Hydrochloride, Rituximab, Oxaliplatin, and Lenalidomide in Treating Patients With Relapsed or Refractory, Aggressive Non-Hodgkin Lymphoma

Not yet reported Auxilio Mutuo Cancer Center 70 participants 1 site

Other conditions: Lymphoma
View official trial listing →
Terminated NCT NCT01307605

Rituximab With or Without Lenalidomide in Treating Patients With Previously Untreated Follicular Lymphoma

Not yet reported Swiss Cancer Institute 154 participants Est. completion 2023-01-25 33 sites

Other conditions: Lymphoma
View official trial listing →
Completed NCT NCT01311687

A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple Myeloma or Relapsed and Refractory Multiple Myeloma and Companion Study

Not yet reported Celgene 455 participants Est. completion 2017-08-29 94 sites

Other conditions: Multiple Myeloma
View official trial listing →
Completed NCT NCT01324947

Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma

Not yet reported Celgene 74 participants Est. completion 2014-07-31 91 sites

Other conditions: Multiple Myeloma
View official trial listing →
Completed NCT NCT01335399

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Not yet reported Bristol-Myers Squibb 748 participants Est. completion 2021-09-03 235 sites Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Status unknown NCT NCT01342692

Best Promising Drug Association With Azacitidine in Higher Risk Myelodysplastic Syndromes

Not yet reported Assistance Publique - Hôpitaux de Paris 320 participants Est. completion 2019-06 1 site Stand-alone

Other conditions: MDS
View official trial listing →
Terminated NCT NCT01348503

Lenalidomide in Combination With a Fixed Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma

Not yet reported Indiana University 5 participants Est. completion 2014-03 1 site Stand-alone

Other conditions: Hepatocellular Carcinoma
View official trial listing →
Completed NCT NCT01348919

Delanzomib (CEP-18770) in Combination With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

Not yet reported, Not yet reported Teva Branded Pharmaceutical Products R&D, Inc. 11 participants Est. completion 2013-03-14 8 sites Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Active, not recruiting NCT NCT01351896

Lenalidomide and Vaccine Therapy in Treating Patients With Early-Stage Asymptomatic Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Not yet reported National Cancer Institute (NCI) 49 participants Est. completion 2027-05-06 1 site Stand-alone

Other conditions: Ann Arbor Stage I Small Lymphocytic Lymphoma, Ann Arbor Stage II Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia With Unmutated Immunoglobulin Heavy Chain Variable-Region Gene, Small Lymphocytic Lymphoma, Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable-Region Gene, Stage 0 Chronic Lymphocytic Leukemia, Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia
View official trial listing →
Completed NCT NCT01352338

Revlimid, Endoxan, Prednison Evaluation After Prior Revlimid Treatment (REPEAT)

Not yet reported, Not yet reported UMC Utrecht 82 participants Est. completion 2016-02 3 sites Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Completed NCT NCT01355705

Phase 1-2 Amrubicin in Combo With Lenalidomide + Weekly Dexamethasone in Relapsed/Refractory Multiple Myeloma

Not yet reported, Not yet reported Michaela Liedtke 14 participants Est. completion 2017-07 1 site Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Completed NCT NCT01373229

Lenalidomide + Plerixafor in Previously Treated Chronic Lymphocytic Leukemia (CLL)

Not yet reported David Rizzieri, MD 21 participants Est. completion 2015-03 1 site Stand-alone

Other conditions: Leukemia, Lymphocytic, Chronic, B-Cell
View official trial listing →
Terminated NCT NCT01374217

Administration of Tadalafil in Conjunction With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma

Not yet reported Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 14 participants Est. completion 2014-01 1 site Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Completed NCT NCT01375140

Ruxolitinib and Lenalidomide for Patients With Myelofibrosis

Not yet reported M.D. Anderson Cancer Center 31 participants Est. completion 2018-09-05 1 site Stand-alone

Other conditions: Myeloproliferative Diseases
View official trial listing →
Completed NCT NCT01378091

Study of Lenalidomide and Docetaxel in Subjects With Androgen Independent Prostate Cancer

Not yet reported Columbia University 64 participants Est. completion 2013-09 2 sites Stand-alone

Other conditions: Prostate Cancer
View official trial listing →
Completed NCT NCT01393756

Revlimid Dose 25 mg in Association With (R-CHOP) in the Treatment Follicular Lymphoma

Not yet reported The Lymphoma Academic Research Organisation 80 participants Est. completion 2015-11 24 sites Stand-alone

Other conditions: Follicular Lymphoma
View official trial listing →
Terminated NCT NCT01403246

Chlorambucil + Lenalidomide and Lenalidomide Maintenance in Untreated Elderly With Chronic Lymphocytic Leukemia (CLL)

Not yet reported, Not yet reported Gruppo Italiano Malattie EMatologiche dell'Adulto 9 participants Est. completion 2015-01 10 sites Stand-alone

Other conditions: Chronic Lymphocytic Leukemia
View official trial listing →
Completed NCT NCT01408199

Study To Evaluate The Safety And Efficacy Of Lenalidomide For Refractory Cutaneous Lupus

Not yet reported Hospital Universitari Vall d'Hebron Research Institute 15 participants Est. completion 2011-08 1 site Stand-alone

Other conditions: Cutaneous Lupus
View official trial listing →
Terminated NCT NCT01422486

Phase 2 Study of Telintra® in Deletion 5q Myelodysplastic Syndrome

Not yet reported Telik 2 participants Est. completion 2013-02 5 sites

Other conditions: Myelodysplastic Syndrome (MDS)
View official trial listing →
Completed NCT NCT01430546

Non-interventional Study on Time to Response and Quality of Life in Relapsed/Refractory Multiple Myeloma When Treated With Lenalidomide in Second Line

Hareth Nahi 133 participants 1 site

Other conditions: Multiple Myeloma
View official trial listing →
Completed NCT NCT01433965

Study of Lenalidomide in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

Not yet reported University of California, Davis 16 participants Est. completion 2021-01-12 1 site Stand-alone

Other conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome
View official trial listing →
Completed NCT NCT01440582

Combination Therapy of Lenalidomide/Bortezomib/Dexamethasone and Panobinostat in Transplant Eligible New Diagnosed Multiple Myeloma (MM) Patients

Not yet reported M.D. Anderson Cancer Center 77 participants Est. completion 2019-02-28 1 site Stand-alone

Other conditions: Myeloma
View official trial listing →
Terminated NCT NCT01442714

Azacitidine + Lenalidomide Combo in the Elderly With Previously Treated AML & High-Risk MDS

Not yet reported Stanford University 33 participants Est. completion 2014-05 1 site Stand-alone

Other conditions: Leukemia, Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)
View official trial listing →
Completed NCT NCT01450215

Randomized Trial Comparing Lenalidomide With Low Dose Dexamethasone Versus Lenalidomide in Second Line Multiple Myeloma

Not yet reported Karolinska University Hospital 62 participants 2 sites Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Completed NCT NCT01459211

Pilot Study to Establish Safety & Efficacy of a Combination of Dexamethasone and Lenalidomide in Patients With Relapsed or Refractory Chronic Lymphocytic Leukaemia (CLL)

Not yet reported University College, London 12 participants Est. completion 2016-02 2 sites

Other conditions: Chronic Lymphocytic Leukemia
View official trial listing →
Completed NCT NCT01460420

Sequential Trial on Reduced Intensity Conditioning (RIC) Allogeneic Transplantation

Not yet reported, Not yet reported European Myeloma Network B.V. 49 participants Est. completion 2017-06-29 10 sites Stand-alone

Other conditions: Hematologic Malignancies, Multiple Myeloma
View official trial listing →
Completed NCT NCT01460940

A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's Lymphoma

Not yet reported Ohio State University Comprehensive Cancer Center 24 participants Est. completion 2016-11-16 2 sites Stand-alone

Other conditions: Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma, Adult Mixed Cellularity Hodgkin Lymphoma, Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma, Adult Nodular Sclerosis Hodgkin Lymphoma, Recurrent Adult Hodgkin Lymphoma
View official trial listing →
Completed NCT NCT01476787

Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma

Not yet reported Celgene 1030 participants Est. completion 2024-04-30 36 sites Stand-alone

Other conditions: Follicular Lymphoma
View official trial listing →
Completed NCT NCT01497093

Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Not yet reported Celgene 34 participants Est. completion 2019-07-23 6 sites

Other conditions: Multiple Myeloma
View official trial listing →
Withdrawn NCT NCT01501370

Vorinostat Plus Lenalidomide and Dexamethasone or Lenalidomide Plus Dexamethasone in Multiple Myeloma Patients Who Experience Biochemical Relapse During Lenalidomide Maintenance Therapy

Not yet reported Tiziana Marangon Est. completion 2012-01 8 sites Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Terminated NCT NCT01518465

Dalteparin, Lenalidomide, and Low-Dose Dexamethasone in Treating Patients With Previously Untreated Multiple Myeloma

Not yet reported University of Southern California 13 participants Est. completion 2017-10-31 1 site Stand-alone

Other conditions: Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
View official trial listing →
Completed NCT NCT01553357

Lenalidomide and Dexamethasone in Primary Plasma Cell Leukemia

Not yet reported IRCCS Centro di Riferimento Oncologico della Basilicata 23 participants Est. completion 2011-09 1 site

Other conditions: Primary Plasma Cell Leukemia
View official trial listing →
Terminated NCT NCT01555281

Nelfinavir and Lenalidomide/Dexamethasone in Progressive Multiple Myeloma

Not yet reported, Not yet reported Swiss Cancer Institute 33 participants Est. completion 2022-06-08 11 sites Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Status unknown NCT NCT01556477

The Efficacy of Azacitidine +/- Lenalidomide in High-risk Myelodysplastic Syndrome (MDS)and Acute Myeloid Leukemia (AML) With Del(5q).

Not yet reported Nordic MDS Group 72 participants Est. completion 2014-11 1 site Stand-alone

Other conditions: Myelodysplastic Syndrome, Acute Myelogenous Leukemia
View official trial listing →
Completed NCT NCT01558167

A Safety and Efficacy Trial of a Combination of Bendamustine, Rituximab and Lenalidomide in Patients With Chronic Lymphocytic Leukemia

Not yet reported, Not yet reported German CLL Study Group 22 participants Est. completion 2015-06 1 site Stand-alone

Other conditions: Chronic Lymphocytic Leukemia
View official trial listing →
Completed NCT NCT01559935

Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD] Therapy for Subjects With Multiple Myeloma

Not yet reported Weill Medical College of Cornell University 74 participants Est. completion 2026-03-19 1 site Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Completed NCT NCT01593410

Study of Lenalidomide and Low-Dose Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma

Not yet reported Celgene 194 participants Est. completion 2013-01-03 13 sites Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Completed NCT NCT01611259

Rituximab Plus Lenalidomide in Patients With Mucosa Associated Lymphoid Tissue

Not yet reported Arbeitsgemeinschaft medikamentoese Tumortherapie 50 participants Est. completion 2015-02 5 sites Stand-alone

Obstructive sleep apnea
View official trial listing →
Completed NCT NCT01629082

Clofarabine Followed By Lenalidomide for High-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia

Not yet reported National Heart, Lung, and Blood Institute (NHLBI) 4 participants Est. completion 2018-06-27 1 site

Other conditions: Myeldysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia, Bone Marrow Diseases, Neutropenia, Acute Myeloid Leukemia (AML)
View official trial listing →
Terminated NCT NCT01649791

Lenalidomide as Chemoprevention in Treating Patients With High-Risk, Early-Stage B-Cell Chronic Lymphocytic Leukemia

Not yet reported Roswell Park Cancer Institute 8 participants Est. completion 2014-10 1 site Stand-alone

Other conditions: B-cell Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Stage 0 Chronic Lymphocytic Leukemia, Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia
View official trial listing →
Completed NCT NCT01651039

Phase II, Single-Center, Oral Panobinostat in Combination With Lenalidomide and Dexamethasone in Multiple Myeloma (MM)

Not yet reported Ajai Chari 32 participants Est. completion 2016-12-21 1 site Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Terminated NCT NCT01659658

Study of Dexamethasone Plus IXAZOMIB (MLN9708) or Physicians Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis

Not yet reported Millennium Pharmaceuticals, Inc. 177 participants Est. completion 2022-07-11 66 sites

Other conditions: Relapsed or Refractory Systemic Light Chain Amyloidosis
View official trial listing →
Completed NCT NCT01668719

S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma

Not yet reported, Not yet reported SWOG Cancer Research Network 142 participants Est. completion 2025-09-22 417 sites Stand-alone

Other conditions: DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, DS Stage III Plasma Cell Myeloma
View official trial listing →
Completed NCT NCT01701076

Bendamustine, Lenalidomide (Revlimid®) and Dexamethasone (BRd) as 2nd-line Therapy for Patients With Relapsed or Refractory Multiple Myeloma

Not yet reported Cantonal Hospital of St. Gallen 50 participants Est. completion 2016-02 1 site Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Completed NCT NCT01704781

Vacc-4x + Lenalidomide vs. Vacc-4x +Placebo in HIV-1-infected Subjects on Antiretroviral Therapy (ART)

Not yet reported, Not yet reported Bionor Immuno AS 36 participants Est. completion 2014-08 4 sites Stand-alone

Other conditions: HIV-1 Infection
View official trial listing →
Completed NCT NCT01706666

Bortezomib Based Consolidation in Multiple Myeloma Patients Completing Stem Cell Transplant

Not yet reported Mayo Clinic 3 participants Est. completion 2016-05-17 4 sites Stand-alone

Other conditions: Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
View official trial listing →
Completed NCT NCT01718379

Lenalidomide in Subject With Low and Intermediate-1 Risk MDS and Without Chromosome 5 Abnormality.

Not yet reported Groupe Francophone des Myelodysplasies 132 participants Est. completion 2016-06 48 sites Stand-alone

Other conditions: Myelodysplastic Syndromes
View official trial listing →
Completed NCT NCT01718743

Ixazomib Citrate and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

Not yet reported M.D. Anderson Cancer Center 64 participants Est. completion 2023-04-12 1 site Stand-alone

Other conditions: Hematopoietic Cell Transplantation Recipient, Plasma Cell Myeloma
View official trial listing →
Completed NCT NCT01723839

Phase II Protocol for CLL With Fludarabine and Cyclophosphamide With Rituximab (FCR) Plus Lenalidomide

Not yet reported Hackensack Meridian Health 21 participants Est. completion 2021-06-08 1 site

Other conditions: Chronic Lymphocytic Leukemia (CLL)
View official trial listing →
Completed NCT NCT01731886

Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma

Not yet reported Columbia University 60 participants Est. completion 2017-04-11 1 site

Other conditions: Multiple Myeloma
View official trial listing →
Completed NCT NCT01732861

Safety Study of CC-292 and Lenalidomide in Subjects With Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma

Not yet reported Celgene 20 participants Est. completion 2019-01-23 11 sites Stand-alone

Other conditions: Leukemia Lymphocytic Chronic B-Cell
View official trial listing →
Completed NCT NCT01737177

Bendamustine/Lenalidomide/Rituximab: Combination as a Second-Line Therapy for 1st Relapsed-Refractory MCL

Not yet reported Fondazione Italiana Linfomi - ETS 42 participants Est. completion 2017-02-02 43 sites Stand-alone

Other conditions: Mantle Cell Lymphoma
View official trial listing →
Completed NCT NCT01743859

Azacitidine and Lenalidomide for Relapsed and Refractory Patients With Acute Myeloid Leukemia

Not yet reported University of Colorado, Denver 37 participants Est. completion 2016-08-03 1 site Stand-alone

Other conditions: Acute Myeloid Leukemia
View official trial listing →
Terminated NCT NCT01750762

Lenalidomide After Allo Transplant

Not yet reported Beth Israel Deaconess Medical Center 1 participants Est. completion 2014-03 1 site Stand-alone

Other conditions: Multiple Myeloma, Lymphoma
View official trial listing →
Withdrawn NCT NCT01754870

Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy Followed by Maintenance Rituximab (Rituxan®) and Lenalidomide (Revlimid®) in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)

Not yet reported University of Wisconsin, Madison Est. completion 2014-08 Stand-alone

Other conditions: Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
View official trial listing →
Completed NCT NCT01766583

A Phase IB Study Of The BTKi CC-292 Combined With Lenalidomide In Adults Patients With Relapsed/Refractory B-Cell Lymphoma

Not yet reported The Lymphoma Academic Research Organisation 18 participants Est. completion 2018-01 6 sites Stand-alone

Other conditions: Relapsed/Refractory B-cell Lymphoma
View official trial listing →
Completed NCT NCT01794039

Pomalidomide or Lenalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Previously Treated With Lenalidomide

Not yet reported Mayo Clinic 9 participants Est. completion 2016-11 1 site Stand-alone

Other conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
View official trial listing →
Active, not recruiting NCT NCT01829568

Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma

Not yet reported National Cancer Institute (NCI) 33 participants Est. completion 2027-06-06 7 sites Stand-alone

Other conditions: Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 1 Non-Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 2 Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 2 Non-Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 3 Non-Contiguous Follicular Lymphoma, Ann Arbor Stage III Grade 1 Follicular Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular Lymphoma, Ann Arbor Stage IV Grade 1 Follicular Lymphoma, Ann Arbor Stage IV Grade 2 Follicular Lymphoma, Ann Arbor Stage IV Grade 3 Follicular Lymphoma
View official trial listing →
Status unknown NCT NCT01830478

Lenalidomide Plus Rituximab (R) in Non Follicular NHL

Not yet reported Gruppo Italiano Studio Linfomi 44 participants Est. completion 2014-10 1 site Stand-alone

Other conditions: Indolent Non Hodgkin Lymphoma
View official trial listing →
Active, not recruiting NCT NCT01856192

Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma

Not yet reported National Cancer Institute (NCI) 349 participants Est. completion 2026-12-31 502 sites Stand-alone

Other conditions: Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma
View official trial listing →
Terminated NCT NCT01891643

PH III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Previously Untreated Multiple Myeloma (ELO 1 Substudy)

Not yet reported Bristol-Myers Squibb 23 participants Est. completion 2020-06-25 14 sites Stand-alone

Other conditions: Newly Diagnosed, Previously Untreated Multiple Myeloma
View official trial listing →
Terminated NCT NCT01927718

Thalidomide to Overcome Lenalidomide Resistance After Autologous Hematopoietic Stem Cell Transplantation (HCT)

Not yet reported M.D. Anderson Cancer Center 10 participants Est. completion 2016-11 1 site Stand-alone

Other conditions: Myeloma
View official trial listing →
Completed NCT NCT01936532

Safety and Efficacy Study of a Triplet Combination of MLN9708, Lenalidomide and Dexamethasone in the Initial Management of Multiple Myeloma (IFM2013-06)

Not yet reported Nantes University Hospital 42 participants Est. completion 2020-06-04 10 sites Stand-alone

Other conditions: Newly Diagnosed Multiple Myeloma
View official trial listing →
Completed NCT NCT01939327

Safety and Efficacy of Revlimid® (Lenalidomide) With Mabthera® (Rituximab) in Non-Hodgkin's Lymphoma

Not yet reported Institut Paoli-Calmettes 34 participants Est. completion 2020-01 1 site Stand-alone

Other conditions: Non-Hodgkin Lymphoma
View official trial listing →
Completed NCT NCT01946477

Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following Lenalidomide-based Therapy in the First or Second Line Setting

Not yet reported Celgene 186 participants Est. completion 2025-05-26 49 sites

Other conditions: Multiple Myeloma
View official trial listing →
Terminated NCT NCT01947309

Observational Registry Study of Chinese Patients Treated With Revlimid (Lenalidomide)

Celgene 176 participants Est. completion 2016-09 17 sites

Other conditions: Multiple Myeloma
View official trial listing →
Completed NCT NCT01995669

Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma

Not yet reported, Not yet reported M.D. Anderson Cancer Center 66 participants Est. completion 2023-01-23 1 site Stand-alone

Other conditions: Grade 3a Follicular Lymphoma, Recurrent Follicular Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Follicular Lymphoma, Refractory Marginal Zone Lymphoma, Refractory Small Lymphocytic Lymphoma
View official trial listing →
Completed NCT NCT01996865

Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.

Not yet reported Celgene 503 participants Est. completion 2024-09-17 126 sites Stand-alone

Other conditions: Lymphoma, Non-Hodgkin
View official trial listing →
Completed NCT NCT01998971

A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma

Not yet reported Janssen Research & Development, LLC 240 participants Est. completion 2024-01-11 22 sites Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Status unknown NCT NCT02004275

Pomalidomide and Dexamethasone With or Without Ixazomib in Treating Patients With Relapsed Multiple Myeloma

Not yet reported, Not yet reported Alliance for Clinical Trials in Oncology 118 participants 336 sites

Other conditions: Multiple Myeloma in Relapse
View official trial listing →
Completed NCT NCT02005289

Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL

Not yet reported Ohio State University Comprehensive Cancer Center 41 participants Est. completion 2025-05-20 1 site Stand-alone

Other conditions: Contiguous Stage II Small Lymphocytic Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Stage I Chronic Lymphocytic Leukemia, Stage I Small Lymphocytic Lymphoma, Stage II Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia, Stage III Small Lymphocytic Lymphoma, Stage IV Chronic Lymphocytic Leukemia, Stage IV Small Lymphocytic Lymphoma
View official trial listing →
Terminated NCT NCT02018523

Lenalidomide Maintenance Therapy in Stage IIIB/IV Non-small Cell Lung Cancer

Not yet reported Jun Zhang 7 participants Est. completion 2016-08 1 site Stand-alone

Other conditions: Carcinoma, Non-Small-Cell Lung
View official trial listing →
Terminated NCT NCT02031419

Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular Lymphoma

Not yet reported Celgene 174 participants Est. completion 2023-12-12 16 sites

Other conditions: Lymphoma, Large B-Cell, Diffuse
View official trial listing →
Terminated NCT NCT02036502

A Study of Pembrolizumab (MK-3475) in Combination With Standard of Care Treatments in Participants With Multiple Myeloma (MK-3475-023/KEYNOTE-023)

Not yet reported Merck Sharp & Dohme LLC 77 participants Est. completion 2020-03-19 Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Terminated NCT NCT02038153

Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant

Not yet reported, Not yet reported Albert Einstein College of Medicine 3 participants Est. completion 2016-01 3 sites Stand-alone

Other conditions: Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia in Remission
View official trial listing →
Terminated NCT NCT02075021

Phase I/II Trial of the Combination of Lenalidomide (Revlimid) and Nab-paclitaxel (Abraxane) in the Treatment of Relapsed/Refractory Multiple Myeloma

Not yet reported, Not yet reported NYU Langone Health 3 participants Est. completion 2015-11 1 site Stand-alone

Other conditions: Relapsed or Refractory Multiple Myeloma
View official trial listing →
Completed NCT NCT02076009

A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

Not yet reported Janssen Research & Development, LLC 569 participants Est. completion 2024-11-21 145 sites Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Completed NCT NCT02086552

Sonidegib and Lenalidomide After Stem Cell Transplant in Treating Patients With Multiple Myeloma

Not yet reported Mayo Clinic 28 participants Est. completion 2021-08-13 1 site Stand-alone

Other conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
View official trial listing →
Completed NCT NCT02112175

Lenalidomide vs Placebo Maintenance Therapy Following Melphalan Prednisone Velcade® Induction Therapy in NDMM

Not yet reported Celgene 46 participants Est. completion 2020-10-12 73 sites Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Terminated NCT NCT02145598

Treatment Optimization in Patients With Untreated Multiple Myeloma

Not yet reported, Not yet reported Dr. med. Lars-Olof Muegge 85 participants Est. completion 2018-12-31 19 sites Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Withdrawn NCT NCT02155634

Continuous Lenalidomide Therapy Versus Observation Following Induction Without Lenalidomide, Pomalidomide or Thalidomide in Myeloma

Not yet reported Celgene Est. completion 2021-03 Stand-alone

Other conditions: Multiple Myeloma, Neoplasms, Plasma Cells, Paraproteinemias, Blood Protein Disorders, Hematologic Diseases, Therapeutic Uses
View official trial listing →
Terminated NCT NCT02188368

Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients

Not yet reported Oncotherapeutics 45 participants Est. completion 2020-10-23 12 sites Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Completed NCT NCT02193698

Efficacy and Safety of Lenalidomide as a Treatment for Recurrent or Refractory POEMS Syndrome Trial

Not yet reported Chiba University 5 participants Est. completion 2016-04 1 site Stand-alone

Other conditions: POEMS Syndrome
View official trial listing →
Terminated NCT NCT02200848

Phase I Study of Lenalidomide, Rituximab and Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Not yet reported Georgetown University 5 participants Est. completion 2017-08-01 1 site Stand-alone

Other conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
View official trial listing →
Completed NCT NCT02213913

Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas

Not yet reported, Not yet reported University of Chicago 55 participants Est. completion 2024-10-29 6 sites Stand-alone

Obstructive sleep apnea Other conditions: Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia, Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma, Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma, Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma, Contiguous Stage II Grade 1 Follicular Lymphoma, Contiguous Stage II Grade 2 Follicular Lymphoma, Contiguous Stage II Grade 3 Follicular Lymphoma, Contiguous Stage II Mantle Cell Lymphoma, Contiguous Stage II Marginal Zone Lymphoma, Contiguous Stage II Small Lymphocytic Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma, Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma, Noncontiguous Stage II Grade 1 Follicular Lymphoma, Noncontiguous Stage II Grade 2 Follicular Lymphoma, Noncontiguous Stage II Grade 3 Follicular Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Marginal Zone Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma, Progressive Hairy Cell Leukemia, Initial Treatment, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Stage 0 Chronic Lymphocytic Leukemia, Stage I Adult Diffuse Large Cell Lymphoma, Stage I Adult Diffuse Mixed Cell Lymphoma, Stage I Adult Diffuse Small Cleaved Cell Lymphoma, Stage I Adult Hodgkin Lymphoma, Stage I Adult Immunoblastic Large Cell Lymphoma, Stage I Chronic Lymphocytic Leukemia, Stage I Grade 1 Follicular Lymphoma, Stage I Grade 2 Follicular Lymphoma, Stage I Grade 3 Follicular Lymphoma, Stage I Mantle Cell Lymphoma, Stage I Marginal Zone Lymphoma, Stage I Small Lymphocytic Lymphoma, Stage II Adult Hodgkin Lymphoma, Stage II Chronic Lymphocytic Leukemia, Stage II Small Lymphocytic Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Mixed Cell Lymphoma, Stage III Adult Diffuse Small Cleaved Cell Lymphoma, Stage III Adult Hodgkin Lymphoma, Stage III Adult Immunoblastic Large Cell Lymphoma, Stage III Chronic Lymphocytic Leukemia, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage III Marginal Zone Lymphoma, Stage III Small Lymphocytic Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Hodgkin Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Chronic Lymphocytic Leukemia, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Small Lymphocytic Lymphoma, Testicular Lymphoma, Untreated Hairy Cell Leukemia, Waldenström Macroglobulinemia
View official trial listing →
Terminated NCT NCT02225275

Lenalidomide and Obinutuzumab in Treating Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Not yet reported M.D. Anderson Cancer Center 9 participants Est. completion 2021-05-19 1 site Stand-alone

Other conditions: Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma
View official trial listing →
Completed NCT NCT02252172

Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma

Not yet reported Janssen Research & Development, LLC 737 participants Est. completion 2024-10-02 206 sites

Other conditions: Multiple Myeloma
View official trial listing →
Completed NCT NCT02260414

Effects of Anticoagulant Preventive Injection in Patients With Blood Cancer

Not yet reported Centre Hospitalier Universitaire de Saint Etienne 19 participants Est. completion 2017-05-09 1 site Stand-alone

Other conditions: Lymphoma, Multiple Myeloma
View official trial listing →
Completed NCT NCT02272803

Phase II Study of Lenalidomide/Dexamethasone With or Without Elotuzumab for Newly Diagnosed MM Patients in Japan

Not yet reported Bristol-Myers Squibb 82 participants Est. completion 2021-07-21 28 sites Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Completed NCT NCT02279654

Non-interventional Study of Lenalidomide in the Clinical Routine Treatment of TD Patients With IPSS Low or Int-1 MDS and Isolated Del(5q)

Celgene 389 participants Est. completion 2022-03-29 148 sites

Other conditions: Myelodysplastic Syndrome
View official trial listing →
Terminated NCT NCT02294357

Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib

Not yet reported Oncotherapeutics 45 participants Est. completion 2020-09-22 7 sites Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Completed NCT NCT02302469

Study of Lenalidomide in Relapse/Refractory Waldenstrom Macroglobulinemia

Not yet reported, Not yet reported University Hospital, Lille 17 participants Est. completion 2017-04 7 sites

Other conditions: Waldenstrom Macroglobulinemia
View official trial listing →
Terminated NCT NCT02309515

Lenalidomide in Improving Immune Response to Vaccine Therapy in Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Monoclonal B Cell Lymphocytosis

Not yet reported Mayo Clinic 12 participants Est. completion 2017-07-21 3 sites Stand-alone

Other conditions: Monoclonal B-Cell Lymphocytosis, Stage 0 Chronic Lymphocytic Leukemia, Stage I Chronic Lymphocytic Leukemia, Stage I Small Lymphocytic Lymphoma
View official trial listing →
Completed NCT NCT02312102

Velcade and Lenalidomide in Patients With Relapsed AML and MDS After Allogeneic Stem Cell Transplantation

Not yet reported Massachusetts General Hospital 22 participants Est. completion 2024-10-07 2 sites Stand-alone

Other conditions: Myelodysplastic Syndrome, Acute Myeloid Leukemia
View official trial listing →
Active, not recruiting NCT NCT02334865

SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy

Not yet reported Roswell Park Cancer Institute 18 participants Est. completion 2026-12-19 2 sites Stand-alone

Other conditions: Partial Response of Multiple Myeloma or Plasma Cell Leukemia, Plasma Cell Myeloma
View official trial listing →
Completed NCT NCT02335983

Phase 1b Study of Weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma

Not yet reported Amgen 107 participants Est. completion 2019-10-28 59 sites Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Completed NCT NCT02336815

Selinexor Treatment of Refractory Myeloma

Not yet reported Karyopharm Therapeutics Inc 202 participants Est. completion 2019-07-26 61 sites Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Completed NCT NCT02348528

Open-label Extended Access Program on Lenalidomide Plus Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma Who Participated in CC-5013-MM021 for at Least 1 Year

Not yet reported Celgene 65 participants Est. completion 2016-09-29 11 sites Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Terminated NCT NCT02353468

Bortezomib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Undergoing Stem Cell Transplant

Not yet reported University of Colorado, Denver 3 participants Est. completion 2011-10 1 site Stand-alone

Other conditions: Refractory Plasma Cell Myeloma
View official trial listing →
Status unknown NCT NCT02354313

Phase III, Randomized Trial: Lenalidomide vs Observation After Induction With Rituximab Followed by Cht and ASCT in MCL Adult Patients

Not yet reported Fondazione Italiana Linfomi - ETS 300 participants Est. completion 2019-01 53 sites Stand-alone

Other conditions: MANTLE CELL LYMPHOMA
View official trial listing →
Withdrawn NCT NCT02371577

Evaluation of the Immune Restoration Potential Of Lenalidomide

Not yet reported University of California, San Diego Est. completion 2020-12 1 site Stand-alone

Other conditions: Chronic Lymphocytic Leukemia (CLL)
View official trial listing →
Withdrawn NCT NCT02371590

Lenalidomide and Obinutuzumab for Previously Untreated CLL

Not yet reported University of California, San Diego Est. completion 2022-12 1 site Stand-alone

Other conditions: Chronic Lymphocytic Leukemia
View official trial listing →
Active, not recruiting NCT NCT02390869

Rituximab and Lenalidomide vs Rituximab Alone as Maintenance After R-chemoterapy for Relapsed/Refractory FL Patients

Not yet reported Fondazione Italiana Linfomi - ETS 128 participants Est. completion 2027-08 28 sites Stand-alone

Other conditions: Lymphoma, Follicular
View official trial listing →
Completed NCT NCT02399085

Open Label Study to Evaluate the Safety and Efficacy of Lenalidomide With MOR00208 in Patients With R-R DLBCL

Not yet reported MorphoSys AG 81 participants Est. completion 2023-04-19 57 sites Stand-alone

Other conditions: Diffuse Large B-cell Lymphoma
View official trial listing →
Completed NCT NCT02405364

Front-line Therapy With Carfilzomib, Lenalidomide, and Dexamethasone Induction

Not yet reported University Hospital, Toulouse 46 participants Est. completion 2019-11-25 11 sites Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Completed NCT NCT02406144

Trial Studying Maintenance Treatment With Lenalidomide and Dexamethasone Versus Lenalidomide, Dexamethasone and MLN9708 After Autologous Hematopoietic Stem Cell Transplantation in Patients With Newly-diagnosed Symptomatic Multiple Myeloma

Not yet reported PETHEMA Foundation 316 participants Est. completion 2017-11 74 sites Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Completed NCT NCT02481934

Clinical Trial of Expanded and Activated Autologous NK Cells to Treat Multiple Myeloma

Not yet reported Joaquín Martínez López, MD, PhD 5 participants Est. completion 2016-10 1 site Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Terminated NCT NCT02516423

Ixazomib Citrate, Lenalidomide, Dexamethasone, and Zoledronic Acid or Zoledronic Acid Alone After Radiation Therapy in Treating Patients With Solitary Plasmacytoma of Bone

Not yet reported Alliance for Clinical Trials in Oncology 11 participants Est. completion 2025-09-30 388 sites Stand-alone

Other conditions: Solitary Osseous Plasmacytoma
View official trial listing →
Terminated NCT NCT02516696

BiRd vs. Rd as Initial Therapy in Multiple Myeloma

Not yet reported Weill Medical College of Cornell University 12 participants Est. completion 2022-07-22 2 sites Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Active, not recruiting NCT NCT02523040

Lenalidomide for Adult Histiocyte Disorders

Not yet reported Dana-Farber Cancer Institute 12 participants Est. completion 2026-12 1 site Stand-alone

Other conditions: Langerhans Cell Histiocytosis (LCH), Histiocytoses Erdheim-chester Disease, Histiocytic Sarcoma (HS)
View official trial listing →
Completed NCT NCT02537808

Non-interventional Study of Lenalidomide / Dexamethasone as First Line Therapy in Patients With Multiple Myeloma

iOMEDICO AG 172 participants Est. completion 2023-09-13 1 site

Other conditions: Multiple Myeloma
View official trial listing →
Completed NCT NCT02556905

A Study to Collect and Evaluate the Safety and Efficacy Information of Korean Multiple Myeloma Patients Treated With REVLIMID®, After Approval of Marketing Authorization for New Drug in Korea

Celgene 624 participants Est. completion 2016-11-30 25 sites

Other conditions: Multiple Myeloma
View official trial listing →
Completed NCT NCT02561273

Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma

Not yet reported, Not yet reported University of Nebraska 54 participants Est. completion 2020-11-01 8 sites Stand-alone

Other conditions: Anaplastic Large Cell Lymphoma, ALK-Negative, Anaplastic Large Cell Lymphoma, ALK-Positive, Hepatosplenic T-Cell Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified, Stage II Angioimmunoblastic T-cell Lymphoma, Stage II Enteropathy-Associated T-Cell Lymphoma, Stage III Angioimmunoblastic T-cell Lymphoma, Stage III Enteropathy-Associated T-Cell Lymphoma, Stage IV Angioimmunoblastic T-cell Lymphoma, Stage IV Enteropathy-Associated T-Cell Lymphoma
View official trial listing →
Completed NCT NCT02568553

Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma

Not yet reported National Cancer Institute (NCI) 35 participants Est. completion 2025-11-24 24 sites Stand-alone

Other conditions: Recurrent Burkitt Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Grade 3a Follicular Lymphoma, Recurrent Grade 3b Follicular Lymphoma, Recurrent Gray-Zone Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mediastinal Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Burkitt Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Refractory Grade 1 Follicular Lymphoma, Refractory Grade 2 Follicular Lymphoma, Refractory Grade 3 Follicular Lymphoma, Refractory Grade 3a Follicular Lymphoma, Refractory Gray-Zone Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Marginal Zone Lymphoma, Refractory Mediastinal Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory Small Lymphocytic Lymphoma
View official trial listing →
Status unknown NCT NCT02575144

GEM-CLARIDEX: Ld vs BiRd

Not yet reported PETHEMA Foundation 286 participants Est. completion 2024-10 26 sites Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Terminated NCT NCT02579863

Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185)

Not yet reported Merck Sharp & Dohme LLC 310 participants Est. completion 2020-07-13 Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Completed NCT NCT02608515

A Retrospective Chart Review Study of the Outcomes of 2nd Line Therapy With LEn/Dex in Greek Patients With R/R Multiple MyEloma and the Treatment PatterNs Following Progressive Disease

Genesis Pharma S.A. 207 participants Est. completion 2016-09 1 site

Other conditions: Relapsed/Refractory Multiple Myeloma
View official trial listing →
Completed NCT NCT02612779

A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone and Elotuzumab in Combination With Nivolumab in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.

Not yet reported Bristol-Myers Squibb 74 participants Est. completion 2020-06-12 22 sites

Other conditions: Multiple Myeloma
View official trial listing →
Completed NCT NCT02633137

Sequential Chemotherapy and Lenalidomide Followed by Rituximab and Lenalidomide Maintenance for Untreated Mantle Cell Lymphoma

Not yet reported Memorial Sloan Kettering Cancer Center 49 participants Est. completion 2023-11-07 7 sites Stand-alone

Other conditions: Mantle Cell Lymphoma, Untreated
View official trial listing →
Active, not recruiting NCT NCT02659293

Trial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma

Not yet reported University of Chicago 180 participants Est. completion 2027-11 3 sites Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Completed NCT NCT02692339

Safety Study of Lenalidomide/Dexamethasone to Treat Patients With Relapsed or Refractory Multiple Myeloma

Celgene 22 participants Est. completion 2018-12-12 12 sites

Other conditions: Multiple Myeloma
View official trial listing →
Completed NCT NCT02697344

Gossypol Acetic Acid With Lenalidomide and Dexamethasone in Treating Patients With Relapsed Symptomatic Multiple Myeloma

Not yet reported Mayo Clinic 10 participants Est. completion 2023-12-20 1 site Stand-alone

Other conditions: Recurrent Plasma Cell Myeloma
View official trial listing →
Completed NCT NCT02721043

Safety and Immunogenicity of Personalized Genomic Vaccine to Treat Malignancies

Not yet reported Nina Bhardwaj 13 participants Est. completion 2020-06-08 1 site Stand-alone

Other conditions: Solid Tumors
View official trial listing →
Completed NCT NCT02733042

A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia

Not yet reported, Not yet reported Celgene 106 participants Est. completion 2022-08-21 66 sites Stand-alone

Other conditions: Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell
View official trial listing →
Withdrawn NCT NCT02802163

Induction Therapy for Multiple Myeloma With Carfilzomib, Lenalidomide,Dexamethasone,Panobinostat

Not yet reported, Not yet reported H. Lee Moffitt Cancer Center and Research Institute Est. completion 2020-12 Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Completed NCT NCT02871219

Obinutuzumab and Lenalidomide in Treating Patients With Previously Untreated Stage II-IV Grade 1-3a Follicular Lymphoma

Not yet reported M.D. Anderson Cancer Center 96 participants Est. completion 2024-06-26 1 site Stand-alone

Other conditions: Ann Arbor Stage II Grade 1 Follicular Lymphoma, Ann Arbor Stage II Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 1 Follicular Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage IV Grade 1 Follicular Lymphoma, Ann Arbor Stage IV Grade 2 Follicular Lymphoma, Bulky Disease, Fatigue, Fever, Grade 3a Follicular Lymphoma, Night Sweats, Splenomegaly, Weight Loss
View official trial listing →
Terminated NCT NCT02897830

Ixazomib, Lenalidomide, Dexamethasone Induction and Extended Consolidation Plus Lenalidomide Maintenance in Multiple Myeloma

Not yet reported University Hospital, Toulouse 46 participants Est. completion 2020-08-31 1 site Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Terminated NCT NCT02898259

Lenalidomide, Ixazomib, and Rituximab as Front-Line Therapy for High Risk Indolent B-Cell Lymphoma

Not yet reported, Not yet reported Brian Hill 19 participants Est. completion 2022-06-06 2 sites Stand-alone

Other conditions: B Cell Lymphoma, Lymphoma
View official trial listing →
Completed NCT NCT02903381

A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering Myeloma

Not yet reported Dana-Farber Cancer Institute 8 participants Est. completion 2021-09-16 1 site Stand-alone

Other conditions: Smoldering Multiple Myeloma
View official trial listing →
Terminated NCT NCT02906332

Pembrolizumab + Lenalidomide Post Autologous Stem Cell Transplant (ASCT) in High-risk Multiple Myeloma (MM)

Not yet reported Hackensack Meridian Health 12 participants Est. completion 2022-05 1 site Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Active, not recruiting NCT NCT02911142

Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma

Not yet reported, Not yet reported National Cancer Institute (NCI) 17 participants Est. completion 2028-10-01 1 site Stand-alone

Other conditions: Primary Effusion Lymphoma, B-Cell Neoplasm
View official trial listing →
Completed NCT NCT02921802

A Study of Special Use Results Surveillance of Revlimid 5mg Capsules

Celgene 4626 participants Est. completion 2013-03-29 1 site

Other conditions: Multiple Myeloma, Myelodysplastic Syndromes
View official trial listing →
Completed NCT NCT02921893

Ixazomib Citrate, Lenalidomide, and Dexamethasone in Treating Patients With POEMS Syndrome

Not yet reported Mayo Clinic 21 participants Est. completion 2024-05-13 1 site Stand-alone

Other conditions: Plasmacytoma, POEMS Syndrome
View official trial listing →
Completed NCT NCT02922543

A Safety and Efficacy Study of Revlimid® 5 mg Capsules in Patients With Relapsed or Refractory Multiple Myeloma Who Have Received Long-term Treatment With it Under the Actual Condition of Use

Celgene 361 participants Est. completion 2014-10-11 1 site

Other conditions: Multiple Myeloma
View official trial listing →
Completed NCT NCT02969837

Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma

Not yet reported University of Chicago 46 participants Est. completion 2025-12-01 3 sites Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Withdrawn NCT NCT03000634

2015-09: a Phase II Randomized, Open-label Study of Anti-signaling Lymphocytic Activation Molecule Monoclonal Antibody During Maintenance Therapy

Not yet reported University of Arkansas Est. completion 2017-04-01 Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Completed NCT NCT03003520

A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma

Not yet reported Celgene 46 participants Est. completion 2022-04-24 20 sites Stand-alone

Other conditions: Lymphoma, Large B-Cell, Diffuse
View official trial listing →
Active, not recruiting NCT NCT03004287

2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy

Not yet reported University of Arkansas 50 participants Est. completion 2028-10 1 site Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Completed NCT NCT03012880

Ixazomib Citrate, Lenalidomide, Dexamethasone, and Daratumumab in Treating Patients With Newly Diagnosed Multiple Myeloma

Not yet reported Mayo Clinic 80 participants Est. completion 2022-12-15 1 site Stand-alone

Other conditions: Plasma Cell Myeloma
View official trial listing →
Terminated NCT NCT03015792

Ibrutinib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Ineligible for Transplant

Not yet reported Mayo Clinic 18 participants Est. completion 2022-10-18 1 site Stand-alone

Other conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
View official trial listing →
Terminated NCT NCT03031730

Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma

Not yet reported National Cancer Institute (NCI) 35 participants Est. completion 2024-07-24 7 sites Stand-alone

Other conditions: Plasmacytoma, Recurrent Multiple Myeloma, Refractory Multiple Myeloma
View official trial listing →
Active, not recruiting NCT NCT03070327

BCMA Targeted CAR T Cells With or Without Lenalidomide for the Treatment of Multiple Myeloma

Not yet reported Memorial Sloan Kettering Cancer Center 20 participants Est. completion 2027-02 1 site Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Completed NCT NCT03098589

Revlimid® Capsules Drug Use-results Surveillance (Relapsed or Refractory ATLL)

Celgene 1149 participants Est. completion 2020-09-18 1 site

Other conditions: Lymphoma
View official trial listing →
Completed NCT NCT03106324

A Safety Study of Lenalidomide in Previously Untreated Adult Multiple Myeloma Patients Who Are Not Eligible for Transplant

Celgene 911 participants Est. completion 2026-01-14 125 sites

Other conditions: Multiple Myeloma
View official trial listing →
No Longer Available NCT NCT03126617

Expanded Access to Elotuzumab (Empliciti) for Multiple Myeloma

Bristol-Myers Squibb

Other conditions: Multiple Myeloma
View official trial listing →
Withdrawn NCT NCT03191981

Pembrolizumab Cyclophosphamide and Lenalidomide for Patients With Relapsed Multiple Myeloma

Not yet reported, Not yet reported University of Leeds Est. completion 2017-08-01 4 sites Stand-alone

Other conditions: Myeloma Multiple
View official trial listing →
Completed NCT NCT03224507

Monoclonal Antibody-Based Sequential Therapy for Deep Remission in Multiple Myeloma

Not yet reported University of Alabama at Birmingham 123 participants Est. completion 2023-06-30 4 sites Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Completed NCT NCT03269136

PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma

Not yet reported Pfizer 101 participants Est. completion 2024-01-19 37 sites Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Active, not recruiting NCT NCT03319667

A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

Not yet reported Sanofi 475 participants Est. completion 2027-06-30 104 sites Stand-alone

Other conditions: Plasma Cell Myeloma
View official trial listing →
Completed NCT NCT03359460

Ibrutinib and Lenalidomide in Treating Patients With Myelodysplastic Syndrome

Not yet reported University of California, Davis 4 participants Est. completion 2019-11-17 1 site Stand-alone

Other conditions: Myelodysplastic Syndrome, Previously Treated Myelodysplastic Syndrome, Refractory High Risk Myelodysplastic Syndrome, Secondary Myelodysplastic Syndrome, Therapy-Related Myelodysplastic Syndrome
View official trial listing →
Status unknown NCT NCT03367143

Lenalidomide Plus ICE in the Treatment of Refractory and Relapsed DLBCL

Not yet reported Ruijin Hospital 39 participants Est. completion 2020-12 1 site Stand-alone

Other conditions: Diffuse Large B-Cell Lymphoma Refractory
View official trial listing →
Withdrawn NCT NCT03373305

Brentuximab Vedotin and Lenalidomide in Treating Patients With Relapsed or Refractory T-Cell Lymphomas

Not yet reported City of Hope Medical Center Est. completion 2019-04-26 1 site Stand-alone

Other conditions: CD30-Positive Neoplastic Cells Present, Folliculotropic Mycosis Fungoides, Recurrent Mycosis Fungoides, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Mycosis Fungoides, Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Sezary Syndrome
View official trial listing →
Completed NCT NCT03375567

Global Response Assessment by Advanced Imaging and Myeloma Lesion Biopsies During Induction Therapy of Multiple Myeloma With Carfilzomib Lenalidomide Dexamethasone

Not yet reported Yale University 28 participants Est. completion 2022-01-14 1 site Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Terminated NCT NCT03376477

Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission

Not yet reported Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 24 participants Est. completion 2025-05-30 1 site Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Terminated NCT NCT03379051

Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHL

Not yet reported, Not yet reported TG Therapeutics, Inc. 78 participants Est. completion 2022-06-16 3 sites Stand-alone

Other conditions: Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma
View official trial listing →
Completed NCT NCT03413800

Len/Dex/DLI in Relapsed Multiple Myeloma After Allogeneic Stem Cell Transplant

Not yet reported Ciusss de L'Est de l'Île de Montréal 10 participants Est. completion 2024-03-27 1 site Stand-alone

Other conditions: Relapsed Hematologic Malignancy, Multiple Myeloma
View official trial listing →
Completed NCT NCT03416374

A Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based Therapy

Not yet reported Takeda 45 participants Est. completion 2021-05-28 23 sites Stand-alone

Other conditions: Relapsed and/or Refractory Multiple Myeloma
View official trial listing →
Completed NCT NCT03433365

Monitoring of Deep of Response During Lenalidomide Maintenance in MM Patients Achieving at Least Very Good Partial Response (MRD)

Fondazione EMN Italy Onlus 70 participants Est. completion 2017-08 1 site

Other conditions: Multiple Myeloma
View official trial listing →
Completed NCT NCT03477539

Daratumumab in Treating Transplant-Eligible Patients With Multiple Myeloma

Not yet reported Mayo Clinic 49 participants Est. completion 2025-03-24 1 site Stand-alone

Other conditions: Plasma Cell Myeloma
View official trial listing →
Completed NCT NCT03495960

Study on Tailored Treatment in Elderly Patients With Newly Diagnosed Primary Lymphoma of Central Nervous System

Not yet reported International Extranodal Lymphoma Study Group (IELSG) 72 participants Est. completion 2024-12-12 34 sites Stand-alone

Other conditions: Primary Central Nervous System Lymphoma
View official trial listing →
Active, not recruiting NCT NCT03500445

Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma

Not yet reported University of Chicago 75 participants Est. completion 2026-06 1 site Stand-alone

Other conditions: Myeloma, Multiple Myeloma
View official trial listing →
Completed NCT NCT03570892

Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma

Not yet reported Novartis Pharmaceuticals 330 participants Est. completion 2026-02-03 67 sites

Other conditions: Non-Hodgkin Lymphoma
View official trial listing →
Completed NCT NCT03631043

Personalized Vaccine in Treating Patients With Smoldering Multiple Myeloma

Not yet reported M.D. Anderson Cancer Center 30 participants Est. completion 2025-12-10 1 site Stand-alone

Other conditions: Smoldering Plasma Cell Myeloma
View official trial listing →
Status unknown NCT NCT03641456

VRD as Induction Followed by VR Maintenance in Patients With Newly Diagnosed High Risk Multiple Myeloma

Not yet reported Sun Yat-sen University 50 participants Est. completion 2025-12-30 1 site Stand-alone

Other conditions: Myeloma, Newly Diagnosed, High Risk
View official trial listing →
Status unknown NCT NCT03669445

Study Association of Lenalidomide, Ixazomib, Dexamethasone and Daratumumab in Newly Diagnosed Standard Risk Multiple Myeloma

Not yet reported University Hospital, Toulouse 45 participants Est. completion 2024-12 12 sites Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Terminated NCT NCT03701711

Lenalidomide in Anti-MAG Neuropathy: Phase 1b Study

Not yet reported Ohio State University 11 participants Est. completion 2022-02-28 2 sites Stand-alone

Other conditions: Demyelinating Sensorimotor Neuropathy
View official trial listing →
Completed NCT NCT03703167

Ibrutinib With Rituximab and Lenalidomide for Patients With Recurrent/Refractory Primary or Secondary Central Nervous System Lymphoma (PCNSL/SCNSL)

Not yet reported Memorial Sloan Kettering Cancer Center 25 participants Est. completion 2026-01-26 7 sites Stand-alone

Other conditions: Primary Central Nervous System Lymphoma (PCNSL), Secondary Central Nervous System Lymphoma (SCNSL)
View official trial listing →
Status unknown NCT NCT03720041

Myeloma XIV: Frailty-adjusted Therapy in Transplant Non-Eligible Patients With Newly Diagnosed Multiple Myeloma

Not yet reported University of Leeds 740 participants Est. completion 2024-12 110 sites Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Terminated NCT NCT03733691

Ph 2 Maintenance Trial: Ixazomib vs Ixazomib-Lenalidomide for MM Patients

Not yet reported Oncotherapeutics 19 participants Est. completion 2023-10-19 1 site Stand-alone

Other conditions: Newly Diagnosed Multiple Myeloma
View official trial listing →
Completed NCT NCT03767257

A Study of Colesevelam for Lenalidomide-Associated Diarrhea

Not yet reported Memorial Sloan Kettering Cancer Center 25 participants Est. completion 2024-11-27 7 sites Stand-alone

Other conditions: Multiple Myeloma, Diarrhea
View official trial listing →
Withdrawn NCT NCT03785184

A Study of Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of Newly Diagnosed t(11;14)-Positive Multiple Myeloma in Subjects Who Are Ineligible for High-Dose Therapy

Not yet reported AbbVie Est. completion 2019-08-22 22 sites Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Status unknown NCT NCT03795571

Lenalidomide, Rituximab, Gemcitabine, Oxaliplatin and Dexamethasone in Relapse and Refractory DLBCL

Not yet reported The First Affiliated Hospital with Nanjing Medical University 12 participants Est. completion 2019-12-31 1 site Stand-alone

Other conditions: Diffuse Large B-cell Lymphoma Recurrent, Diffuse Large B Cell Lymphoma Refractory
View official trial listing →
Active, not recruiting NCT NCT03829371

STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA

Not yet reported University of Turin, Italy 450 participants Est. completion 2030-01-03 1 site Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Status unknown NCT NCT03837873

DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma

Not yet reported Institute of Hematology & Blood Diseases Hospital, China 118 participants Est. completion 2024-09-01 6 sites Stand-alone

Other conditions: Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Transformed Lymphoma
View official trial listing →
Completed NCT NCT03859427

A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Not yet reported Amgen 454 participants Est. completion 2023-03-31 108 sites

Other conditions: Relapsed or Refractory Multiple Myeloma
View official trial listing →
Completed NCT NCT03901963

A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant

Not yet reported Janssen Research & Development, LLC 200 participants Est. completion 2026-05-04 73 sites Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Status unknown NCT NCT03903406

Quality of Life, Symptoms and Treatment Satisfaction in Adult Patients With Relapsed and/or Refractory Multiple Myeloma, Receiving Ixazomib (Ninlaro®) in Combination With Lenalidomide and Dexamethasone in a Real World Setting: Pilot Study

Multinational Center for Quality of Life Research, Russia 40 participants Est. completion 2021-11

Other conditions: Relapsed and/or Refractory Multiple Myeloma
View official trial listing →
Status unknown NCT NCT03908138

RDD Versus VDD in Newly Diagnosed Patients With Multiple Myeloma

Not yet reported Shandong Provincial Hospital 120 participants Est. completion 2022-12-31 1 site

Other conditions: Hematologic Neoplasms, Multiple Myeloma, Efficacy, Safety
View official trial listing →
Completed NCT NCT03941860

Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial

Not yet reported National Cancer Institute (NCI) 1 participants Est. completion 2025-01-31 222 sites Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Status unknown NCT NCT03949062

Study Evaluating the Safety and Efficacy of iR2 in Untreated and Unfit Elderly Patients With DLBCL

Not yet reported Ruijin Hospital 30 participants Est. completion 2022-05 1 site Stand-alone

Other conditions: Diffuse Large B Cell Lymphoma
View official trial listing →
Active, not recruiting NCT NCT03980171

Study of Lenalidomide, Venetoclax and Obinutuzumab in Patients With Treatment-Naïve Follicular Lymphoma

Not yet reported, Not yet reported Peter MacCallum Cancer Centre, Australia 50 participants Est. completion 2026-11 3 sites Stand-alone

Other conditions: Follicular Lymphoma
View official trial listing →
Completed NCT NCT03984097

A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)

Not yet reported Takeda 50 participants Est. completion 2026-03-25 9 sites Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Status unknown NCT NCT04025593

Biomarker Guided Treatment in DLBCL

Not yet reported Ruijin Hospital 128 participants Est. completion 2023-06-01 1 site Stand-alone

Other conditions: Diffuse Large B Cell Lymphoma
View official trial listing →
Status unknown NCT NCT04049864

DNA Vaccination Against Neuroblastoma

Not yet reported Belarusian Research Center for Pediatric Oncology, Hematology and Immunology 12 participants Est. completion 2023-12-31 1 site Stand-alone

Other conditions: Relapsed Neuroblastoma
View official trial listing →
Completed NCT NCT04053933

Observational Study Towards the Impact of Newly Started Treatment in MDS on QoL

University Hospital, Antwerp 70 participants Est. completion 2021-07-31 21 sites

Other conditions: Myelodysplastic Syndromes
View official trial listing →
Status unknown NCT NCT04063189

Clinical Trial of Clarithromycin, Lenalidomide and Dexamethasone in the Treatment of the First Relapsed Multiple Myeloma

Not yet reported The First Hospital of Jilin University 100 participants Est. completion 2020-02-01 1 site Stand-alone

Other conditions: Multiple Myeloma in Relapse
View official trial listing →
Active, not recruiting NCT NCT04071457

S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration

Not yet reported SWOG Cancer Research Network 1100 participants Est. completion 2040-07-01 842 sites Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Completed NCT NCT04094142

Acalabrutinib With Rituximab and Lenalidomide in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Not yet reported Seoul National University Hospital 66 participants Est. completion 2022-05-15 1 site Stand-alone

Other conditions: Non-hodgkin Lymphoma,B Cell
View official trial listing →
Status unknown NCT NCT04120350

R2-MTX With Lenalidomide Maintenance in Newly-diagnosed PCNSL：a Multicenter Phase Ib/II Stuty

Not yet reported, Not yet reported Peking Union Medical College Hospital 47 participants Est. completion 2024-08 1 site Stand-alone

Other conditions: Primary Central Nervous System Lymphoma
View official trial listing →
Status unknown NCT NCT04129710

A Trial to Compare Ibrutinib Versus Lenalidomide in Combination With MRE-chemotherapy for Adult Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL)

Not yet reported Second Affiliated Hospital, Zhejiang University, School of Medicine 120 participants Est. completion 2025-12-31 1 site Stand-alone

Other conditions: Recurrent/RefractoryPrimary Central Nervous System Lymphoma (PCNSL)
View official trial listing →
Active, not recruiting NCT NCT04133636

A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma

Not yet reported Janssen Research & Development, LLC 208 participants Est. completion 2028-08-25 47 sites Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Status unknown NCT NCT04152577

R2 and Combination Chemotherapy Versus R and Combination Chemotherapy in Newly Diagnosed Highly Aggressive B-NHL

Not yet reported Shandong Provincial Hospital 200 participants Est. completion 2022-01-01 1 site Stand-alone

Other conditions: Lymphoma, B-Cell
View official trial listing →
Active, not recruiting NCT NCT04181827

A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma

Not yet reported Janssen Research & Development, LLC 419 participants Est. completion 2027-03-31 88 sites

Other conditions: Multiple Myeloma
View official trial listing →
Completed NCT NCT04217967

Ixazomib, Lenalidomide, and Combination for Maintenance in NDMM Patients

Not yet reported Peking Union Medical College Hospital 211 participants Est. completion 2024-06-30 1 site Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Status unknown NCT NCT04231370

Lenalidomide and Sintilimab for Relapsed/Refractory NK/T-cell Lymphoma

Not yet reported Beijing Tongren Hospital 20 participants Est. completion 2022-12-31 1 site Stand-alone

Other conditions: NK/T Cell Lymphoma Nos
View official trial listing →
Status unknown NCT NCT04277845

Randomized Phase II Study in Elderly Patients With Newly Diagnosed Multiple Myeloma

Not yet reported Samsung Medical Center 49 participants Est. completion 2025-03 1 site Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Completed NCT NCT04298372

Frontline Lenalidomide for AL Amyloidosis Involving Myocardium

Not yet reported Seoul National University Hospital 2 participants Est. completion 2021-11-25 1 site

Other conditions: Amyloidosis Cardiac
View official trial listing →
Approved For Marketing NCT NCT04300803

Expanded Access Program for Tafasitamab (MOR00208) in R/R DLBCL

MorphoSys AG

Other conditions: DLBCL
View official trial listing →
Completed NCT NCT04309942

Evaluation Study on Performance of Guided Clinical Pharmacy Consultation in Patients With Multiple Myeloma on First Oral Anticancer Treatment

Not yet reported Centre Hospitalier Universitaire de Nīmes 60 participants Est. completion 2023-05-30 3 sites

Other conditions: Multiple Myeloma
View official trial listing →
Terminated NCT NCT04405167

Tasquinimod for the Treatment of Relapsed or Refractory Myeloma

Not yet reported University of Pennsylvania 30 participants Est. completion 2025-07-01 1 site Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Active, not recruiting NCT NCT04430894

KRDI in Transplant-Eligible MM

Not yet reported Massachusetts General Hospital 50 participants Est. completion 2026-12-30 3 sites Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Completed NCT NCT04436107

Zanubrutinib, in Combination With Lenalidomide, With or Without Rituximab in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Not yet reported BeiGene 66 participants Est. completion 2024-03-28 10 sites Stand-alone

Other conditions: Relapsed/Refractory Diffuse Large B-Cell Lymphoma
View official trial listing →
Completed NCT NCT04447027

Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies

Not yet reported National Cancer Institute (NCI) 26 participants Est. completion 2025-12-17 1 site Stand-alone

Other conditions: Cutaneous T-Cell Lymphoma, Mature T-cell Malignancies, Peripheral T-Cell Lymphoma, Relapsed/ Refractory T-cell Malignancies
View official trial listing →
Active, not recruiting NCT NCT04447716

An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment

Not yet reported Thomas Jefferson University 4 participants Est. completion 2027-04 1 site Stand-alone

Other conditions: Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Follicular Lymphoma, Recurrent Indolent Adult Non-Hodgkin Lymphoma, Recurrent Marginal Zone Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Follicular Lymphoma, Refractory Indolent Adult Non-Hodgkin Lymphoma, Refractory Marginal Zone Lymphoma
View official trial listing →
Active, not recruiting NCT NCT04497961

A Study of Health-Related Quality of Life in People With Multiple Myeloma Receiving Daratumumab or Lenalidomide

Not yet reported Memorial Sloan Kettering Cancer Center 95 participants Est. completion 2027-08 7 sites Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Status unknown NCT NCT04518982

Sintilimab and Lenalidomide as a Treatment for CAEBV

Not yet reported Zhao Wang 51 participants Est. completion 2021-08-01 1 site Stand-alone

Other conditions: CAEBV
View official trial listing →
Suspended NCT NCT04539236

Luspatercept and Lenalidomide (L2) in Lower-risk, Non-del(5q) MDS Patients

Not yet reported, Not yet reported Mikkael Sekeres, MD 50 participants Est. completion 2029-08-01 5 sites Stand-alone

Other conditions: Myelodysplastic Syndromes
View official trial listing →
Active, not recruiting NCT NCT04542824

Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)

Not yet reported, Not yet reported Genmab 78 participants Est. completion 2027-09 15 sites Stand-alone

Other conditions: Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Small Lymphocytic Lymphoma
View official trial listing →
Status unknown NCT NCT04544059

Lenalidomide Plus R-CHOP for CNS Relapse Prophylaxis in Diffuse Large B-cell Lymphoma

Not yet reported Nanfang Hospital, Southern Medical University 87 participants Est. completion 2024-10-01 1 site Stand-alone

Other conditions: Diffuse Large B Cell Lymphoma
View official trial listing →
Completed NCT NCT04578600

CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma

Not yet reported Joseph Tuscano 8 participants Est. completion 2025-02-21 1 site Stand-alone

Obstructive sleep apnea Other conditions: Indolent B-Cell Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Follicular Lymphoma, Recurrent Hairy Cell Leukemia, Recurrent Lymphoplasmacytic Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Follicular Lymphoma, Refractory Hairy Cell Leukemia, Refractory Lymphoplasmacytic Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Small Lymphocytic Lymphoma
View official trial listing →
Withdrawn NCT NCT04607772

Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)

Not yet reported, Not yet reported Karyopharm Therapeutics Inc Est. completion 2025-12 18 sites Stand-alone

Other conditions: Relapsed or Refractory Diffuse Large B-Cell Lymphoma
View official trial listing →
Completed NCT NCT04618081

Revlimid® Capsules General Drug Use-results Surveillance (Relapsed or Refractory FL and MZL)

Celgene 151 participants Est. completion 2025-03-27 1 site

Other conditions: Lymphoma Nonhodgkin
View official trial listing →
Status unknown NCT NCT04622579

Lenalidomide Combined With Rituximab as Front-line Therapy for DLBCL Patients Aged Over 80 Years

Not yet reported Guangdong Provincial People's Hospital 20 participants Est. completion 2023-03-31 1 site Stand-alone

Other conditions: Diffuse Large B Cell Lymphoma, Age Over 80 Years
View official trial listing →
Active, not recruiting NCT NCT04653246

Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM

Not yet reported Jacob Laubach, MD 52 participants Est. completion 2029-01-13 1 site Stand-alone

Other conditions: Multiple Myeloma, Newly Diagnosed Multiple Myeloma (NDMM), Autologous Stem Cell Transplant
View official trial listing →
Active, not recruiting NCT NCT04656951

Daratumumab for First Line Treatment of Transplant-ineligible Myeloma Patients Followed by Daratumumab Re-treatment at First Relapse

Not yet reported University of Cologne 67 participants Est. completion 2031-12 1 site Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Active, not recruiting NCT NCT04661007

To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL)

Not yet reported, Not yet reported Incyte Biosciences Japan GK 72 participants Est. completion 2026-12-31 23 sites Stand-alone

Other conditions: Non Hodgkins Lymphoma, Diffuse Large B-cell Lymphoma
View official trial listing →
Status unknown NCT NCT04674514

APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple Myeloma

Not yet reported, Not yet reported Ascentage Pharma Group Inc. 48 participants Est. completion 2024-05 12 sites Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Completed NCT NCT04697160

Observational Retrospective Cohort Study of Systemic Therapies for R/R DLBCL

MorphoSys AG 3573 participants Est. completion 2021-05-07 165 sites

Other conditions: Diffuse Large B Cell Lymphoma
View official trial listing →
Active, not recruiting NCT NCT04717700

Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in TIE Newly Diagnosed MM Patients

Not yet reported Ida Bruun Kristensen 50 participants Est. completion 2029-06-01 11 sites Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Active, not recruiting NCT NCT04782687

Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma

Not yet reported US Oncology Research 73 participants Est. completion 2026-05-31 10 sites Stand-alone

Other conditions: Multiple Myeloma, Myeloma Multiple, Kahler Disease, Myeloma, Plasma Cell, Myeloma-Multiple, Myelomatosis, Plasma Cell Myeloma
View official trial listing →
Active, not recruiting NCT NCT04790474

Ixazomib-pomalidomide-dexamethasone as Second or Third-line Combination Treatment for Patients With Relapsed and Refractory Multiple Myeloma Previously Treated With Daratumumab, Lenalidomide and Bortezomib

Not yet reported Tel-Aviv Sourasky Medical Center 61 participants Est. completion 2028-01-01 7 sites Stand-alone

Other conditions: Multiple Myeloma in Relapse, Refractory Multiple Myeloma
View official trial listing →
Status unknown NCT NCT04818372

Dose Escalation and Expansion Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma and Lymphoma

Not yet reported Keymed Biosciences Co.Ltd 87 participants Est. completion 2023-04 3 sites Stand-alone

Other conditions: Multiple Myeloma, Lymphoma
View official trial listing →
Status unknown NCT NCT04842487

R2-CHOP in Untreated DEL-DLBCL：An Open-lable，Multicenter，Phase II Study

Not yet reported Sun Yat-sen University 80 participants Est. completion 2023-12-30 Stand-alone

Other conditions: DLBCL
View official trial listing →
Terminated NCT NCT04892264

Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple Myeloma

Not yet reported Mayo Clinic 5 participants Est. completion 2024-03-18 1 site Stand-alone

Other conditions: Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
View official trial listing →
Status unknown NCT NCT04935580

Study of FasT CAR-T GC012F Injection in High Risk TE NDMM Patients

Not yet reported, Not yet reported Shanghai Changzheng Hospital 20 participants Est. completion 2023-07-01 1 site Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Status unknown NCT NCT04938297

Rituximab,Zanubrutinib in Combination With Lenalidomide, Followed by Zanubrutinib or Lenalidomide Maintenance in Patients With Primary or Secondary CNS Lymphoma

Not yet reported Henan Cancer Hospital 100 participants Est. completion 2025-12-31 1 site Stand-alone

Other conditions: Central Nervous System Lymphoma
View official trial listing →
Completed NCT NCT04939844

REST - Replacing Steroids in the Transplant Ineligble

Not yet reported Oslo University Hospital 51 participants Est. completion 2024-08-31 4 sites Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Active, not recruiting NCT NCT04978584

Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study

Not yet reported M.D. Anderson Cancer Center 62 participants Est. completion 2027-01-16 1 site Stand-alone

Other conditions: Diffuse Large B-Cell Lymphoma
View official trial listing →
Completed NCT NCT04981795

realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL

Incyte Corporation 102 participants Est. completion 2026-01-23 26 sites

Other conditions: Diffuse Large B-cell Lymphoma
View official trial listing →
Active, not recruiting NCT NCT05025800

ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma

Not yet reported, Not yet reported M.D. Anderson Cancer Center 47 participants Est. completion 2028-03-21 1 site Stand-alone

Other conditions: Aggressive B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular Lymphoma, Ann Arbor Stage III Marginal Zone Lymphoma, Ann Arbor Stage IV Grade 1 Follicular Lymphoma, Ann Arbor Stage IV Grade 2 Follicular Lymphoma, Ann Arbor Stage IV Grade 3 Follicular Lymphoma, Ann Arbor Stage IV Marginal Zone Lymphoma, Composite Lymphoma, Indolent B-Cell Non-Hodgkin Lymphoma, Refractory Aggressive B-Cell Non-Hodgkin Lymphoma, Refractory Follicular Lymphoma, Refractory Grade 3b Follicular Lymphoma, Refractory High Grade B-Cell Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Marginal Zone Lymphoma, Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma, Richter Syndrome
View official trial listing →
Completed NCT NCT05032820

Upfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple Myeloma

Not yet reported Medical College of Wisconsin 40 participants Est. completion 2025-02-20 15 sites Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Active, not recruiting NCT NCT05050097

A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma

Not yet reported Janssen Research & Development, LLC 166 participants Est. completion 2027-04-07 31 sites Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Active, not recruiting NCT NCT05060627

Study of Belantamab Mafodotin in Combination With Kd for the Treatment of Relapsed Myeloma Patients, Refractory to Lenalidomide

Not yet reported, Not yet reported PETHEMA Foundation 60 participants Est. completion 2028-05-30 15 sites

Other conditions: Relapsed Multiple Myeloma
View official trial listing →
Status unknown NCT NCT05076097

A Study of OLR in First-line Treatment of Mantle Cell Lymphoma

Not yet reported Tianjin Medical University Cancer Institute and Hospital 29 participants Est. completion 2023-10-15 1 site Stand-alone

Other conditions: Mantle Cell Lymphoma
View official trial listing →
Terminated NCT NCT05090566

MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma

Not yet reported Pfizer 46 participants Est. completion 2026-03-11 25 sites Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Active, not recruiting NCT NCT05123131

Isa-RVD Study in Patients With Newly Diagnosed Multiple Myeloma

Not yet reported Cancer Trials Ireland 54 participants Est. completion 2027-12-15 5 sites Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Status unknown NCT NCT05147493

A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment

Not yet reported Hellenic Society of Hematology 51 participants Est. completion 2025-02 6 sites Stand-alone

Other conditions: Multiple Myeloma, Renal Impairment, Neoplasms, Plasma Cell, Neoplasms by Histologic Type, Neoplasms, Paraproteinemias, Blood Protein Disorders, Hematologic Diseases
View official trial listing →
Status unknown NCT NCT05186558

Penpulimab Plus R2-GemOx Regimen in Relapsed or Refractory DLBCL

Not yet reported The First Affiliated Hospital with Nanjing Medical University 54 participants Est. completion 2026-02-15 4 sites Stand-alone

Other conditions: Lymphoma, Large B-Cell, Diffuse, Neoplasms by Histologic Type
View official trial listing →
Active, not recruiting NCT NCT05231629

Sequential Therapy in Multiple Myeloma Guided by MRD Assessments

Not yet reported University of Alabama at Birmingham 300 participants Est. completion 2029-12 10 sites

Other conditions: Multiple Myeloma
View official trial listing →
Active, not recruiting NCT NCT05257083

A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma

Not yet reported Stichting European Myeloma Network 759 participants Est. completion 2040-08 106 sites Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Status unknown NCT NCT05280275

A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible

Not yet reported, Not yet reported Hellenic Society of Hematology 36 participants Est. completion 2026-03-15 2 sites Stand-alone

Other conditions: Multiple Myeloma, Neoplasms, Neoplasms, Plasma Cell, Gammopathy, Monoclonal, Paraproteinemias, Blood Protein Disorders, Haematologic Disease, Corneal Disease
View official trial listing →
Completed NCT NCT05284591

Non-interventional Study to Evaluate Patient and Healthcare Provider Satisfaction of Daratumumab Use in the Treatment of First-line Daratumumab, Lenalidomide, Dexamethasone (DRd) Multiple Myeloma Patients in Germany Depending on Application Route (sc or iv)

iOMEDICO AG 96 participants Est. completion 2024-09-20 1 site

Other conditions: Multiple Myeloma, Newly Diagnosed, Transplant Ineligible, Patient Satisfaction, Patient Preference, Personal Satisfaction
View official trial listing →
Terminated NCT NCT05288062

Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma

Not yet reported Mayo Clinic 17 participants Est. completion 2024-07-25 4 sites Stand-alone

Other conditions: Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma, Smoldering Plasma Cell Myeloma
View official trial listing →
Status unknown NCT NCT05290090

ZR2 Followed by Immunochemotherapy in Elderly Patients With Newly-diagnosed DLBCL

Not yet reported Zhejiang Cancer Hospital 31 participants Est. completion 2025-12-01 1 site Stand-alone

Other conditions: Diffuse Large B Cell Lymphoma
View official trial listing →
Completed NCT NCT05318391

Translational Study of Molecular Classification of Relapsed/Refractory Diffuse Large B-cell Lymphoma

Shanghai Zhongshan Hospital 324 participants Est. completion 2022-03-30 1 site

Other conditions: Lymphoma, Large B-Cell, Diffuse, Gene Expression Profiling
View official trial listing →
Active, not recruiting NCT NCT05335018

GPL in Patients with Relapsed/refractory Diffuse Large B Cell Lymphoma

Not yet reported Seoul National University Hospital 76 participants Est. completion 2026-11-30 1 site Stand-alone

Other conditions: Relapsed/refractory Diffuse Large B Cell Lymphoma
View official trial listing →
Status unknown NCT NCT05351346

Genotype-guided Treatment in DLBCL

Not yet reported Ruijin Hospital 1100 participants Est. completion 2026-06-01 1 site Stand-alone

Other conditions: Diffuse Large B Cell Lymphoma
View official trial listing →
Active, not recruiting NCT NCT05354557

Study of Iberdomide in People With Multiple Myeloma Who Have Had an Autologous Hematopoietic Stem Cell Transplant (AHCT)

Not yet reported Memorial Sloan Kettering Cancer Center 16 participants Est. completion 2027-04-26 8 sites Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Status unknown NCT NCT05422027

Selinexor Plus VRd in High Risk Newly Diagnosed Multiple Myeloma

Not yet reported, Not yet reported Xia Zhongjun 42 participants Est. completion 2025-12-31 4 sites Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Active, not recruiting NCT NCT05429268

Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND)

Not yet reported Incyte Corporation 82 participants Est. completion 2027-04-01 61 sites Stand-alone

Other conditions: Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma
View official trial listing →
Status unknown NCT NCT05477797

Id and Rd Maintenance Regimens After Induction of Remission in Multiple Myeloma.

Not yet reported RenJi Hospital 420 participants Est. completion 2026-01-15 1 site Stand-alone

Other conditions: Progression Free Survival, Overall Survival, Maintenance
View official trial listing →
Status unknown NCT NCT05495620

Long-term KRd in Relapsed and/or Refractory Multiple Myeloma

Dong-A University Hospital 300 participants Est. completion 2023-09-30

Other conditions: Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
View official trial listing →
Status unknown NCT NCT05497102

Carfilzomib, Lenalidomide, and Dexamethasone Re-induction Followed by the 2nd ASCT in Multiple Myeloma Patients Relapsed After the 1st ASCT

Not yet reported Samsung Medical Center 58 participants Est. completion 2025-12 1 site Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Not yet recruiting NCT NCT05581875

A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory

Not yet reported, Not yet reported Hellenic Society of Hematology 48 participants Est. completion 2026-10-31

Other conditions: Multiple Myeloma, Multiple Myeloma in Relapse, Neoplasms, Gammopathy, Monoclonal, Paraproteinemias, Blood Protein Disorders, Haematologic Disease, Corneal Disease, Neoplasms, Plasma Cell
View official trial listing →
Terminated NCT NCT05641324

A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (OMNIA-2)

Not yet reported Anaveon AG 4 participants Est. completion 2023-07-12 11 sites Stand-alone

Other conditions: Multiple Myeloma, Relapsed Cancer, Refractory Multiple Myeloma, Adult Disease, Hematologic Diseases
View official trial listing →
Enrolling by invitation NCT NCT05669989

International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab

Not yet reported Sanofi 70 participants Est. completion 2028-11-30 37 sites Stand-alone

Other conditions: Plasma Cell Myeloma
View official trial listing →
Terminated NCT NCT05675319

Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy

Not yet reported Universitätsklinikum Hamburg-Eppendorf 28 participants Est. completion 2025-03-21 30 sites

Other conditions: Multiple Myeloma
View official trial listing →
Active, not recruiting NCT NCT05683171

A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma

Not yet reported, Not yet reported M.D. Anderson Cancer Center 16 participants Est. completion 2027-09-30 1 site Stand-alone

Other conditions: Lymphoma
View official trial listing →
Active, not recruiting NCT NCT05690984

Elimination of Minimal Residual Disease After Transplant

Not yet reported Medical College of Wisconsin 30 participants Est. completion 2027-07 1 site Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Active, not recruiting NCT NCT05732961

Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms

Not yet reported H. Lee Moffitt Cancer Center and Research Institute 6 participants Est. completion 2026-09 1 site Stand-alone

Other conditions: Myelodysplastic Syndromes, Myeloproliferative Neoplasm, Anemia
View official trial listing →
Status unknown NCT NCT05784987

R-MINE+X in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Not yet reported The First Affiliated Hospital with Nanjing Medical University 60 participants Est. completion 2025-01-01 Stand-alone

Other conditions: Diffuse Large B-cell Lymphoma
View official trial listing →
Status unknown NCT NCT05787964

Immunity to Infection in Healthy Participants and Participants With Cancer

University Hospital Tuebingen 200 participants Est. completion 2024-09-01 1 site

Other conditions: Influenza, SARS-CoV-2, Hematologic Malignancy, Solid Tumor
View official trial listing →
Terminated NCT NCT05788289

A Study of Tafasitamab and Lenalidomide in People With Mantle Cell Lymphoma

Not yet reported Memorial Sloan Kettering Cancer Center 4 participants Est. completion 2024-08-01 7 sites Stand-alone

Other conditions: Mantle Cell Lymphoma, MCL
View official trial listing →
Status unknown NCT NCT05831969

Lenalidomide to Reverse Drug Resistance After First-line Treatment of Advanced HCC

Not yet reported Shenyang Tenth People's Hospital 23 participants Est. completion 2025-10-05 Stand-alone

Other conditions: Advanced HCC
View official trial listing →
Active, not recruiting NCT NCT05849610

Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple Myeloma

Not yet reported PETHEMA Foundation 30 participants Est. completion 2029-07 10 sites Stand-alone

Other conditions: High-Risk de Novo Multiple Myeloma
View official trial listing →
Active, not recruiting NCT NCT05850286

A Study of VRd-based Regimen Combined With CART-ASCT-CART2 Treatment in NDMM Patients With P53 Abnormalities

Not yet reported Institute of Hematology & Blood Diseases Hospital, China 20 participants Est. completion 2028-04 1 site Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Active, not recruiting NCT NCT05860036

A Study of VRd-based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With New-diagnosed Multiple Myeloma

Not yet reported Institute of Hematology & Blood Diseases Hospital, China 40 participants Est. completion 2028-03-10 1 site Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Active, not recruiting NCT NCT05870917

A Study of VRD-based Regimen Combined With CART-ASCT-CART2 Treatment in Patients With Primary Plasma Cell Leukemia

Not yet reported Institute of Hematology & Blood Diseases Hospital, China 20 participants Est. completion 2027-04 1 site Stand-alone

Other conditions: Plasma Cell Leukemia
View official trial listing →
Active, not recruiting NCT NCT05888493

A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma

Not yet reported Novartis Pharmaceuticals 109 participants Est. completion 2031-02-20 30 sites

Other conditions: Follicular Lymphoma (FL)
View official trial listing →
Active, not recruiting NCT NCT05950165

A Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjects With Refractory or Relapsed Non-Hodgkin's Lymphoma

Not yet reported, Not yet reported Cho Pharma Inc. 37 participants Est. completion 2026-12-23 9 sites Stand-alone

Other conditions: Non-Hodgkin Lymphoma
View official trial listing →
Status unknown NCT NCT06033820

Zanubrutinib+Lenalidomide+R-ICE in Relapsed/Refractory DLBCL

Not yet reported RenJi Hospital 20 participants Est. completion 2025-06-30 1 site Stand-alone

Other conditions: Diffuse Large B-cell Lymphoma Recurrent, Diffuse Large B Cell Lymphoma Refractory
View official trial listing →
Active, not recruiting NCT NCT06042725

MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma

Not yet reported Mayo Clinic 16 participants Est. completion 2027-05-29 1 site Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Active, not recruiting NCT NCT06045806

A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation

Not yet reported Celgene 79 participants Est. completion 2029-11-20 101 sites Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Completed NCT NCT06069024

Population Pharmacokinetic Study Based on Quantitative Pharmacology in Patients With Lenalidomide

Qianfoshan Hospital 38 participants Est. completion 2023-05-31 1 site

Other conditions: Multiple Myeloma, Myelodysplastic Syndromes, Lymphoma
View official trial listing →
Completed NCT NCT06163040

A Study to Evaluate the Safety of Empliciti® (Elotuzumab) When Treating Patients With Multiple Myeloma in Taiwan

Bristol-Myers Squibb 7 participants Est. completion 2025-03-17 4 sites

Other conditions: Relapsed or Refractory Multiple Myeloma
View official trial listing →
Not yet recruiting NCT NCT06177028

MCLENA-2: A Phase II Clinical Trial for the Assessment of Lenalidomide in Patients With Mild Cognitive Impairment

Not yet reported St. Joseph's Hospital and Medical Center, Phoenix 45 participants Est. completion 2027-01-02 Stand-alone

Other conditions: Cognitive Impairment, Mild, Cognitive Dysfunction, Amyloid Plaque, Neurodegenerative Disease, Hereditary, Inflammation, Brain
View official trial listing →
Status unknown NCT NCT06189833

Phase 2 Study Applying MRD Techniques for Participants With Previously Untreated Multiple Myeloma Treated With D-VRd Prior To and After High-dose Therapy Followed by ASCT - TAURUS

Not yet reported Stichting European Myeloma Network 200 participants Est. completion 2025-12 31 sites Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Active, not recruiting NCT NCT06191744

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma

Not yet reported Genmab 1095 participants Est. completion 2037-11 266 sites Stand-alone

Other conditions: Follicular Lymphoma (FL)
View official trial listing →
Active, not recruiting NCT NCT06192888

A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma

Not yet reported Memorial Sloan Kettering Cancer Center 39 participants Est. completion 2028-01-08 10 sites Stand-alone

Other conditions: Mantle Cell Lymphoma, MCL
View official trial listing →
Active, not recruiting NCT NCT06208150

A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide

Not yet reported Janssen Research & Development, LLC 838 participants Est. completion 2028-12-31 242 sites

Other conditions: Multiple Myeloma
View official trial listing →
Completed NCT NCT06212596

Selinexor, Cyclophosphamide and Prednisone in Myeloma

Not yet reported University of Leeds 66 participants Est. completion 2023-11-14 13 sites Stand-alone

Other conditions: Relapsed or Refractory Multiple Myeloma
View official trial listing →
Status unknown NCT NCT06240520

Optimizing Reversal of HIV Latency With Combination Therapy

Not yet reported, Not yet reported Erasmus Medical Center 49 participants Est. completion 2025-10 3 sites Stand-alone

Other conditions: Hiv
View official trial listing →
Status unknown NCT NCT06251648

Acute Lymphoblastic Leukaemia Related to Lenalidomide (LenALL)

University Hospital, Caen 300 participants Est. completion 2024-03-31 1 site

Other conditions: Cancer
View official trial listing →
Withdrawn NCT NCT06348147

Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell Transplantation

Not yet reported UNC Lineberger Comprehensive Cancer Center Est. completion 2029-05 1 site Stand-alone

Other conditions: Newly Diagnosed Multiple Myeloma, Multiple Myeloma, Autologous Stem Cell Transplantation
View official trial listing →
Not yet recruiting NCT NCT06441097

Efficacy of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL

Not yet reported Ruijin Hospital 152 participants Est. completion 2027-12-31 Stand-alone

Other conditions: Diffuse Large B-Cell Lymphoma
View official trial listing →
Not yet recruiting NCT NCT06516978

A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL

Not yet reported The First Affiliated Hospital with Nanjing Medical University 528 participants Est. completion 2029-04-01 Stand-alone

Other conditions: Diffuse Large B Cell Lymphoma
View official trial listing →
Not yet recruiting NCT NCT06748521

Dynamic CtDNA-guided Targeted Therapy in DLBCL

Not yet reported Ruijin Hospital 108 participants Est. completion 2028-06-01 Stand-alone

Other conditions: Diffuse Large B Cell Lymphoma (DLBCL)
View official trial listing →
Not yet recruiting NCT NCT06913192

Efficacy of Sequential BCMA CAR-T Cell Therapy Following Autologous Hematopoietic Stem Cell Transplantation in Transplant-eligible Newly Diagnosed Multiple Myeloma

Not yet reported Xuzhou Medical University 50 participants Est. completion 2028-02-28 Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Not yet recruiting NCT NCT06931704

Comparison of Elranatamab and Lenalidomide Versus Daratumumab and Lenalidomide as Post-transplant Maintenance Therapy in Patients With Newly Diagnosed Myeloma (ElMMA)

Not yet reported Nantes University Hospital 176 participants Est. completion 2031-11-30 36 sites Stand-alone

Other conditions: Multiple Myeloma
View official trial listing →
Not yet recruiting NCT NCT06965244

Lenalidomide vs Methotrexate in Difficult-to-treat Cutaneous Lupus Erythematosus

Not yet reported Assistance Publique - Hôpitaux de Paris 122 participants Est. completion 2029-04-01 Stand-alone

Other conditions: Cutaneous Lupus Erythematosus (CLE)
View official trial listing →
Withdrawn NCT NCT07030699

A Study of Epcoritamab With Lenalidomide and Tafasitamab in People With Diffuse Large B Cell Lymphoma

Not yet reported Memorial Sloan Kettering Cancer Center Est. completion 2026-03-31 Stand-alone

Other conditions: Lymphoma
View official trial listing →
Not yet recruiting NCT NCT07122609

Pirtobrutinib in Combination With Rituximab, Gemcitabine, Oxaliplatin With or Without Polatuzumab Vedotin in Covalent BTK Inhibitor-Pretreated Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Not yet reported Ruijin Hospital 22 participants Est. completion 2027-08-15 1 site Stand-alone

Other conditions: Relapsed and Refractory DLBCL
View official trial listing →
Completed NCT NCT07184424

Real-world Study of Lenalidomide After First-line Treatment Lenvatinib With PD-1 in Advanced HCC

Not yet reported Beijing Tsinghua Chang Gung Hospital 24 participants Est. completion 2025-04-30 1 site Stand-alone

Other conditions: HCC - Hepatocellular Carcinoma
View official trial listing →
Not yet recruiting NCT NCT07247097

ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma

Not yet reported Massachusetts General Hospital 160 participants Est. completion 2035-12-01 3 sites Stand-alone

Other conditions: Multiple Myeloma, Newly Diagnosed Multiple Myeloma, Transplant Ineligible, Newly Diagnosed Multiple Myeloma (NDMM)
View official trial listing →
Not yet recruiting NCT NCT07532473

REal World MAIA UK OutcomEs

The Royal Wolverhampton Hospitals NHS Trust 300 participants Est. completion 2028-07 1 site

Other conditions: Myeloma
View official trial listing →
Not yet recruiting NCT NCT07585747

A Exploratory Study on Untreated Follicular Lymphoma With Orelabrutinib, Tafasitamab, and Lenalidomide

Not yet reported Institute of Hematology & Blood Diseases Hospital, China 27 participants Est. completion 2030-12-31 5 sites Stand-alone

Other conditions: Follicular Lymphoma
View official trial listing →
Not yet recruiting NCT NCT07735637

A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).

Not yet reported AstraZeneca 750 participants Est. completion 2039-11-09 65 sites Stand-alone

Other conditions: Newly Diagnosed Multiple Myeloma (NDMM)
View official trial listing →
Not yet recruiting NCT NCT07740486

A Study Comparing Treatment With Teclistamab and Talquetamab Versus Daratumumab and Lenalidomide in Patients With Multiple Myeloma After Stem Cell Transplant Who Still Have Detectable Disease

Not yet reported Polish Myeloma Consortium 248 participants Est. completion 2033-04

Other conditions: Multiple Myeloma (MM)
View official trial listing →
Not yet recruiting NCT NCT07764861

A Open-Label Phase in Participants With Multiple Myeloma

Not yet reported Innovent Biologics (Suzhou) Co. Ltd. 120 participants Est. completion 2031-06-30 1 site

Other conditions: Multiple Myeloma
View official trial listing →
Not yet recruiting NCT NCT07814001

Epcoritamab Plus Lenalidomide in Relapsed/Refractory Large B-cell Lymphoma After Second-Line CAR T-cell Therapy

Not yet reported The Lymphoma Academic Research Organisation 55 participants Est. completion 2031-05 15 sites Stand-alone

Other conditions: Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Refractory Large B-cell Lymphoma (LBCL), Refractory T-cell/Histiocyte-rich Large B-cell Lymphoma, Refractory Transformed Follicular Lymphoma, Refractory High-Grade B-Cell Lymphoma, Refractory Follicular Lymphoma Grade 3B
View official trial listing →
Not yet recruiting NCT NCT07828522

F182112 in Combination With Isatuximab and Lenalidomide for the Treatment of Patients With Newly Diagnosed Multiple Myeloma

Not yet reported Institute of Hematology & Blood Diseases Hospital, China 10 participants Est. completion 2028-12-30 Stand-alone

Other conditions: Multiple Myeloma (MM), Transplant-eligible Patients
View official trial listing →

Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

ClinicalTrials.gov — NCT06768489

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.